CASEID,PRIMARYID,CASEVERSION,I_F_CODE,EVENT_DT,MFR_DT,INIT_FDA_DT,FDA_DT,REPT_COD,AUTH_NUM,MFR_NUM,MFR_SNDR,LIT_REF,AGE,AGE_COD,AGE_GRP,SEX,E_SUB,WT,WT_COD,REPT_DT,TO_MFR,OCCP_COD,REPORTER_COUNTRY,OCCR_COUNTRY,DRUGNAME,PT,PRIMARYID_OUTC,OUTC_COD,PRIMARYID_RPSR,RPSR_COD,PRIMARYID_THER,DSG_DRUG_SEQ,START_DT,END_DT,DUR,DUR_COD,PRIMARYID_INDI,INDI_DRUG_SEQ,INDI_PT
11991033,1199103319,19,F,,20230123,20160202,20230130,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-004939,BRISTOL MYERS SQUIBB,Literature citation unavailable,54,YR,A,M,Y,,,20230130,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,1199103319,HO,,,,,,,,,1199103319,1,HIV infection
12985056,1298505610,10,F,,20230215,20161129,20230223,EXP,,CA-APOTEX-2016AP014805,APOTEX,,52,YR,,M,Y,,,20230223,,MD,CA,CA,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,1298505610,CA,,,1298505610,5,,,3080,DAY,1298505610,1,HIV infection
13906408,1390640847,47,F,,20230316,20170825,20230321,EXP,,CA-009507513-0809CAN00001,MERCK,"Harris M, Larsen G, Montaner JSG. Harris M, Larsen G, Montaner JSG. Exacerbation of depression associated with starting raltegravir: a report of four cases.. AIDS. 2008;22(14):1890-2",54,YR,,M,Y,,,20230321,,MD,CA,CA,EFAVIRENZ;SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Diplopia;Drug interaction;Eyelid ptosis;Incorrect route of product administration;Intentional product use issue;Lipodystrophy acquired;Loss of personal independence in daily activities;Mitochondrial toxicity;Off label use;Paranoia;Prescribed overdose;Product use in unapproved indication;Psychiatric decompensation;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,1390640847,HO,,,1390640847,1,20070620,,,,1390640847,1,HIV infection
14165912,1416591211,11,F,,20230101,20171107,20230103,EXP,,GB-GILEAD-2017-0303084,GILEAD,,85,YR,E,M,Y,,,20230103,,MD,GB,GB,EFAVIRENZ,Drug interaction;Renal impairment,1416591211,OT,,,1416591211,1,,,152,DAY,1416591211,1,HIV infection
14221665,142216656,6,F,20170823,20230209,20171124,20230211,EXP,,PHHY2017CO172327,NOVARTIS,,57,YR,,M,Y,54,KG,20230211,,CN,CO,CO,EFAVIRENZ,Abdominal discomfort;Arthralgia;Decreased immune responsiveness;Dizziness;Inappropriate schedule of product administration;Malaise;Pain;Platelet count decreased;Somnolence,142216656,LT,,,142216656,1,20110317,,,,142216656,1,Chronic myeloid leukaemia
14265678,1426567822,22,F,,20230107,20171208,20230111,EXP,,GB-BAUSCH-BL-2017-032451,BAUSCH AND LOMB,,85,YR,,M,Y,,,20230111,,MD,GB,GB,EFAVIRENZ,Drug interaction;Renal impairment,1426567822,OT,,,1426567822,5,,,152,DAY,1426567822,1,Crohn's disease
14277495,142774958,8,F,,20230110,20171212,20230116,EXP,,GB-SHIRE-GB201732945,TAKEDA,,85,YR,,M,Y,,,20230116,,CN,GB,GB,EFAVIRENZ,Drug interaction;Renal impairment,142774958,OT,,,,,,,,,142774958,1,Inflammatory bowel disease
14610366,146103665,5,F,20060602,20230313,20180307,20230322,EXP,CA-HEALTH CANADA-E2B_01366855,CA-ALLERGAN-1812285US,ALLERGAN,"Harris M, Larsen G. Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS. 2008;22(14):ahead of print",,,,M,Y,,,20230322,,HP,CA,CA,SUSTIVA,Anxiety;Condition aggravated;Contraindicated product administered;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,146103665,HO,,,146103665,2,20070729,20060602,355,DAY,146103665,1,Psychotic disorder
15095440,1509544011,11,F,20100629,20230119,20180702,20230124,EXP,,GB-GILEAD-2018-0347475,GILEAD,,43,YR,A,F,Y,43,KG,20230124,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Caesarean section;Hepatic cytolysis;Intentional product use issue;Maternal exposure during pregnancy;Off label use,1509544011,OT,,,1509544011,1,20180205,20180205,4,MON,1509544011,1,HIV infection
15112110,1511211011,11,F,20171006,20230113,20180705,20230118,EXP,,GB-GILEAD-2018-0347708,GILEAD,,3,MON,I,M,Y,,,20230118,,HP,GB,GB,EFAVIRENZ,Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Off label use;Trisomy 18;Ultrasound antenatal screen,1511211011,CA,,,1511211011,1,20171006,20180205,122,DAY,1511211011,1,HIV infection
15114149,1511414948,48,F,20100629,20230201,20180706,20230211,EXP,,GB-AUROBINDO-AUR-APL-2018-033634,AUROBINDO,,3,MON,,M,Y,,,20230211,,MD,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Alopecia;Anaemia;Aspartate aminotransferase increased;Caesarean section;Cleft lip and palate;Device related infection;Diarrhoea;Ejection fraction decreased;Epistaxis;Exposure during pregnancy;Fatigue;Foetal exposure during pregnancy;Gastrooesophageal reflux disease;Gingival swelling;Hepatic cytolysis;Hot flush;Hydrops foetalis;Influenza like illness;Intentional product use issue;Lymphoedema;Maternal exposure during pregnancy;Mucosal inflammation;Off label use;Osteonecrosis of jaw;Rash;Sepsis;Trisomy 18;Ultrasound antenatal screen;Vascular device infection,1511414948,HO,,,1511414948,1,20171006,20180205,4,MON,1511414948,1,HIV infection
15115814,1511581452,52,F,20100629,20230309,20180706,20230313,EXP,,GB-MYLANLABS-2018M1048354,MYLAN,,3,MON,,M,Y,,,20230313,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Caesarean section;Cleft lip and palate;Drug abuse;Exposure during pregnancy;Foetal exposure during pregnancy;Hepatic cytolysis;Hydrops foetalis;Intentional product use issue;Maternal exposure during pregnancy;Off label use;Trisomy 18;Ultrasound antenatal screen,1511581452,DE,,,1511581452,15,20090101,20180205,241,DAY,1511581452,1,HIV infection
15158165,1515816550,50,F,20100629,20230117,20180718,20230130,EXP,,GB-AUROBINDO-AUR-APL-2018-036078,AUROBINDO,,43,YR,,F,Y,43,KG,20230130,,MD,GB,GB,EFAVIRENZ;EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Caesarean section;Cleft lip and palate;Drug abuse;Hepatic cytolysis;Hydrops foetalis;Intentional product use issue;Maternal exposure during pregnancy;Off label use;Trisomy 18;Ultrasound antenatal screen,1515816550,CA,,,1515816550,1,20100610,20180205,4,MON,1515816550,1,HIV infection
15180335,1518033528,28,F,20100629,20230204,20180723,20230213,EXP,,GB-BAUSCH-BL-2018-019695,BAUSCH AND LOMB,,43,YR,,F,Y,43,KG,20230213,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Caesarean section;Cleft lip and palate;Drug abuse;Exposure during pregnancy;Foetal exposure during pregnancy;Hepatic cytolysis;Hydrops foetalis;Intentional product use issue;Maternal exposure during pregnancy;Off label use;Trisomy 18;Ultrasound antenatal screen,1518033528,HO,,,1518033528,4,20171006,20180205,4,MON,1518033528,1,Product used for unknown indication
15204215,1520421529,29,F,20100629,20230212,20180726,20230220,EXP,,GB-BAUSCH-BL-2018-019701,BAUSCH AND LOMB,,16,WK,,M,Y,,,20230220,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Caesarean section;Cleft lip and palate;Exposure during pregnancy;Foetal exposure during pregnancy;Hepatic cytolysis;Hydrops foetalis;Intentional product use issue;Maternal exposure during pregnancy;Off label use;Trisomy 18;Ultrasound antenatal screen,1520421529,DE,,,1520421529,2,20090101,20100610,526,DAY,1520421529,1,Product used for unknown indication
15297051,152970514,4,F,20180521,20230206,20180820,20230210,EXP,,UG-MYLANLABS-2018M1062243,MYLAN,,0,YR,,M,Y,2.6,KG,20230210,,CN,UG,UG,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Congenital umbilical hernia;Foetal exposure during pregnancy;Sepsis neonatal;Talipes,152970514,CA,,,152970514,1,20180521,,,,152970514,1,Product used for unknown indication
15357909,1535790941,41,F,20120521,20220208,20180906,20230211,EXP,,PHHY2018GB086977,NOVARTIS,,43,YR,,F,Y,43,KG,20230211,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Drug abuse;Hepatic cytolysis;Intentional product use issue;Maternal exposure during pregnancy;Off label use;Ultrasound antenatal screen,1535790941,OT,,,1535790941,5,20100610,20180205,4,MON,1535790941,1,Product used for unknown indication
15361880,1536188020,20,F,20171006,20230217,20180907,20230220,EXP,,PHHY2018GB085930,NOVARTIS,,3,MON,,M,Y,,,20230220,,HP,GB,GB,EFAVIRENZ,Alanine aminotransferase increased;Aspartate aminotransferase increased;Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Intentional product use issue;Off label use;Trisomy 18;Ultrasound antenatal screen,1536188020,HO,,,1536188020,2,20090101,20100610,526,DAY,1536188020,1,Foetal exposure during pregnancy
15626751,1562675140,40,F,,20230117,20181116,20230123,EXP,,CA-ABBVIE-18S-028-2552613-00,ABBVIE,,54,YR,,M,Y,,,20230123,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Intentional product use issue;Loss of personal independence in daily activities;Paranoia;Prescribed overdose;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,1562675140,DE,,,,,,,,,1562675140,1,Bipolar disorder
16590194,165901947,7,F,,20230123,20190718,20230203,EXP,,CA-TEVA-2018-CA-968075,TEVA,,44,YR,A,M,Y,,,20230202,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,165901947,HO,,,,,,,,,165901947,1,HIV infection
17044956,1704495612,12,F,,20230320,20191118,20230322,EXP,,CA-BAUSCH-BL-2019-058588,BAUSCH AND LOMB,"Harris M, Larsen G, Montaner J. Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS. 2008;22 (14):1890-1892. doi:10.1097/QAD.0b013e32830e0169",54,YR,,M,Y,,,20230322,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,1704495612,HO,,,,,,,,,1704495612,1,Bipolar disorder
17222608,172226083,3,F,20120521,20230309,20200102,20230323,EXP,,GB-IPCA LABORATORIES LIMITED-IPC-2019-GB-002333,IPCA,,,,,,Y,,,20230323,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Cleft lip and palate;Drug abuse;Exposure during pregnancy;Foetal exposure during pregnancy;Hepatic cytolysis;Hydrops foetalis;Intentional product use issue;Maternal exposure during pregnancy;Off label use;Trisomy 18;Ultrasound antenatal screen,172226083,DE,,,172226083,2,20171006,20180205,123,DAY,172226083,1,Product used for unknown indication
17244332,172443329,9,F,20070101,20230215,20200107,20230221,PER,,US-GILEAD-2019-0444850,GILEAD,,,,A,M,Y,86.168,KG,20230221,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Depression;Drug resistance;Emotional distress;Pain;Renal failure;Skeletal injury,172443329,OT,,,172443329,1,201302,201604,,,172443329,1,HIV infection
17523420,175234205,5,F,20161220,20230104,20200310,20230109,EXP,,US-GILEAD-2020-0454098,GILEAD,,55,YR,A,M,Y,72.562,KG,20230109,,LW,US,US,SUSTIVA,Chronic kidney disease;Economic problem;Emotional distress;End stage renal disease;Pain;Renal failure,175234205,OT,,,175234205,1,20090824,20141119,1913,DAY,175234205,1,HIV infection
17709935,177099353,3,F,20130301,20230222,20200427,20230227,EXP,,US-GILEAD-2020-0460866,GILEAD,,34,YR,A,M,Y,,,20230227,,LW,US,US,SUSTIVA,Arthralgia;Back pain;Bone density decreased;Bone loss;Multiple fractures;Osteonecrosis;Renal injury,177099353,OT,,,177099353,1,201304,2019,,,177099353,1,HIV infection
17723970,177239703,3,F,20151001,20230214,20200429,20230221,EXP,,US-GILEAD-2020-0462309,GILEAD,,59,YR,A,M,Y,72.562,KG,20230221,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Bone density decreased;Bone loss;Cervical vertebral fracture;Chronic kidney disease;Emotional distress;Multiple fractures;Osteonecrosis;Osteopenia;Osteoporosis;Pain;Renal failure,177239703,OT,,,177239703,1,200706,201706,,,177239703,1,HIV infection
18065589,180655896,6,F,,20221230,20200724,20230111,EXP,CA-MHPD-E2B_02992182,CA-Accord-191476,ACCORD,,44,YR,A,M,Y,,,20230111,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,180655896,HO,,,180655896,13,,,365,DAY,180655896,1,Depression
18172099,181720993,3,F,20080101,20230124,20200819,20230206,EXP,,US-GILEAD-2020-0490269,GILEAD,,,,A,F,Y,104.32,KG,20230206,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Depression;Emotional distress;Gout;Pain;Renal injury,181720993,OT,,,181720993,1,2007,2018,,,181720993,1,HIV infection
18193790,181937905,5,F,,20230119,20200825,20230123,EXP,,CA-AstraZeneca-2020SF06056,ASTRAZENECA,,54,YR,,M,Y,,,20230123,,MD,CA,,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,181937905,DE,,,,,,,,,181937905,1,Bipolar disorder
18291577,182915772,2,F,20081201,20230321,20200921,20230327,EXP,,US-GILEAD-2020-0495218,GILEAD,,52,YR,A,M,Y,77.098,KG,20230327,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;End stage renal disease;Gout;Osteoporosis;Pain;Renal disorder,182915772,OT,,,182915772,1,2008,201811,,,182915772,1,HIV infection
18531452,185314523,3,F,,20230118,20201122,20230129,EXP,,CA-JNJFOC-20201124162,JOHNSON AND JOHNSON,,44,YR,A,M,Y,,,20230130,,HP,CA,CA,SUSTIVA,Abdominal pain;Anxiety;Constipation;Depression;Depression suicidal;Depressive symptom;Drug interaction;Gastric infection;Muscle rigidity;Off label use;Pain;Paranoia;Product use in unapproved indication;Psychiatric decompensation;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Rebound effect;Retching;Salivary hypersecretion;Sedation;Suicidal ideation;Tearfulness,185314523,HO,,,185314523,12,,,161,DAY,185314523,1,Major depression
18544053,185440535,5,F,,20230118,20201124,20230123,EXP,,CA-JNJFOC-20201125727,JOHNSON AND JOHNSON,,44,YR,A,M,Y,,,20230123,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychotic disorder;Suicidal ideation;Tearfulness,185440535,HO,,,,,,,,,185440535,1,Depression
18954100,189541005,5,F,,20230320,20210301,20230327,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2021GSK053499,VIIV,,,,,,Y,,,20230327,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,189541005,OT,,,,,,,,,189541005,1,HIV infection
18954111,189541115,5,F,,20230320,20210301,20230327,EXP,,CA-GLAXOSMITHKLINE-CA2021GSK053499,GLAXOSMITHKLINE,,,,,,Y,,,20230327,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,189541115,OT,,,,,,,,,189541115,1,HIV infection
19040806,190408062,2,F,,20230222,20210322,20230307,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-023855,BRISTOL MYERS SQUIBB,,44,YR,A,M,Y,,,20230307,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Hospitalisation;Off label use;Psychiatric decompensation,190408062,OT,,,,,,,,,190408062,1,Product used for unknown indication
19169020,191690203,3,F,,20230123,20210422,20230202,EXP,,CA-TEVA-2021-CA-1901914,TEVA,,44,YR,A,M,Y,,,20230202,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,191690203,HO,,,,,,,,,191690203,1,HIV infection
19215171,192151714,4,F,20190614,20230207,20210504,20230210,EXP,,US-GILEAD-2021-0527872,GILEAD,,63,YR,A,M,Y,113.38,KG,20230210,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Dyspareunia;Emotional distress;Gait disturbance;Insomnia;Multiple fractures;Osteopenia;Osteoporosis;Pain;Pathological fracture;Physical disability;Renal failure;Spinal fracture,192151714,OT,,,192151714,1,2004,202009,4602,DAY,192151714,1,HIV infection
19220333,192203334,4,F,20190225,20230318,20210506,20230321,EXP,,US-GILEAD-2021-0527870,GILEAD,,53,YR,A,M,Y,140.59,KG,20230321,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Bone density decreased;Bone loss;Bone pain;Emotional distress;Fatigue;Osteopenia;Osteoporosis;Pain;Renal injury,192203334,OT,,,192203334,1,2002,201902,,,192203334,1,HIV infection
19568406,195684066,6,F,20090111,20230313,20210714,20230316,EXP,,US-GILEAD-2021-0540483,GILEAD,,43,YR,A,F,Y,108.84,KG,20230316,,LW,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Arthritis;Bone demineralisation;Bone density abnormal;Bone density decreased;Depression;Emotional distress;Foot fracture;Gait disturbance;Insomnia;Malaise;Multiple fractures;Nausea;Osteoporosis;Pain;Tooth loss,195684066,OT,,,195684066,1,2001,2015,,,195684066,1,HIV infection
19604124,196041242,2,F,20141101,20210524,20210723,20230331,EXP,,HR-009507513-2107HRV006804,MERCK,,66,YR,,M,Y,,,20230331,,MD,HR,HR,EFAVIRENZ,Cardiac arrest;Hypertension;Myocardial infarction;Nephropathy,196041242,OT,,,196041242,1,200807,200808,,,196041242,1,HIV infection
19744986,1974498611,11,F,,20230118,20210825,20230123,EXP,,CA-009507513-2108CAN005807,MERCK,,54,YR,,M,Y,,,20230123,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Incorrect route of product administration;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose;Product use in unapproved indication,1974498611,DE,,,,,,,,,1974498611,1,HIV infection
19759214,197592144,4,F,,20230320,20210829,20230328,EXP,,CA-009507513-2108CAN006022,MERCK,,54,YR,,M,Y,,,20230328,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,197592144,OT,,,,,,,,,197592144,1,Product used for unknown indication
19759220,197592203,3,F,,20230316,20210829,20230322,EXP,,CA-009507513-2108CAN006021,MERCK,,,,,M,Y,,,20230322,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,197592203,HO,,,,,,,,,197592203,1,Product used for unknown indication
20119748,201197482,2,F,,20230123,20211126,20230130,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-121861,BRISTOL MYERS SQUIBB,,54,YR,A,M,Y,,,20230131,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Intentional product use issue;Loss of personal independence in daily activities;Off label use,201197482,OT,,,,,,,,,201197482,1,HIV infection
20516396,2051639620,20,F,,20230111,20220225,20230123,EXP,,GB-ORGANON-1711GBR010764,ORGANON,,85,YR,,M,Y,,,20230123,,MD,GB,GB,EFAVIRENZ,Drug interaction;Renal impairment,2051639620,OT,,,2051639620,8,,,152,DAY,2051639620,1,Cardiovascular event prophylaxis
20570145,205701453,3,F,20130101,20230218,20220309,20230222,EXP,,US-GILEAD-2022-0572815,GILEAD,,50,YR,A,M,Y,99.79,KG,20230222,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Condition aggravated;Emotional distress;Pain;Renal failure,205701453,OT,,,205701453,1,2001,2008,,,205701453,1,HIV infection
20571008,205710082,2,F,20060201,20230301,20220309,20230307,EXP,,US-GILEAD-2022-0572948,GILEAD,,40,YR,A,F,Y,90.703,KG,20230307,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Emotional distress;End stage renal disease;Osteopenia;Pain;Protein total increased;Renal impairment,205710082,OT,,,205710082,1,2005,200709,,,205710082,1,HIV infection
20571057,205710572,2,F,20100826,20230127,20220309,20230201,EXP,,US-GILEAD-2022-0572973,GILEAD,,49,YR,A,F,Y,53.977,KG,20230201,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Osteoporosis;Pain;Renal failure,205710572,OT,,,205710572,1,2004,201801,,,205710572,1,HIV infection
20574147,205741473,3,F,20110501,20230131,20220309,20230207,PER,,US-GILEAD-2022-0572977,GILEAD,,48,YR,A,M,Y,,,20230207,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Blood creatinine increased;Bone demineralisation;Chronic kidney disease;Drug ineffective;Emotional distress;Fall;Foot fracture;Loss of personal independence in daily activities;Osteoporosis;Pain;Renal impairment,205741473,HO,,,205741473,1,2010,202011,,,205741473,1,HIV infection
20574238,205742382,2,F,20060201,20230213,20220309,20230217,EXP,,US-GILEAD-2022-0573003,GILEAD,,37,YR,A,M,Y,80.73,KG,20230217,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Chronic kidney disease;Emotional distress;Fanconi syndrome acquired;Pain;Vitamin D deficiency,205742382,HO,,,205742382,1,2002,200606,,,205742382,1,HIV infection
20574617,205746172,2,F,20120101,20230130,20220309,20230202,PER,,US-GILEAD-2022-0572998,GILEAD,,,,A,M,Y,63.492,KG,20230202,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Emotional distress;Pain;Renal failure;Tooth loss,205746172,OT,,,205746172,1,2007,2016,,,205746172,1,Product used for unknown indication
20575030,205750302,2,F,20180101,20230210,20220310,20230215,EXP,,US-GILEAD-2022-0573075,GILEAD,,,,A,M,Y,,,20230215,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Bone demineralisation;Chronic kidney disease;Emotional distress;Osteopenia;Pain,205750302,OT,,,205750302,1,2006,201710,,,205750302,1,HIV infection
20575880,205758802,2,F,20170101,20230227,20220310,20230302,PER,,US-GILEAD-2022-0572849,GILEAD,,,,A,M,Y,,,20230302,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Emotional distress;Fatigue;Pain;Renal impairment,205758802,OT,,,205758802,1,2007,2019,,,205758802,1,HIV infection
20576327,205763272,2,F,20090501,20230226,20220310,20230301,EXP,,US-GILEAD-2022-0572953,GILEAD,,52,YR,A,M,Y,103.87,KG,20230301,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Asthenia;Blood creatinine increased;Bone demineralisation;Chronic kidney disease;Emotional distress;Fatigue;Pain,205763272,OT,,,205763272,1,200904,200905,,,205763272,1,HIV infection
20580300,205803002,2,F,20100201,20230302,20220310,20230307,PER,,US-GILEAD-2022-0572980,GILEAD,,41,YR,A,M,Y,127,KG,20230307,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Depression;Emotional distress;Pain;Proteinuria;Renal failure,205803002,OT,,,205803002,1,2007,201607,,,205803002,1,HIV infection
20646085,206460852,2,F,20100101,20230302,20220329,20230307,EXP,,US-GILEAD-2022-0575360,GILEAD,,,,A,M,Y,81.633,KG,20230307,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;End stage renal disease;Fanconi syndrome acquired;Hyperlipidaemia;Osteoporosis;Pain,206460852,OT,,,206460852,1,2006,201105,,,206460852,1,HIV infection
20646717,206467172,2,F,20160101,20230130,20220329,20230201,EXP,,US-GILEAD-2022-0575246,GILEAD,,,,A,M,Y,74.8,KG,20230201,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Emotional distress;Osteopenia;Osteoporosis;Pain,206467172,OT,,,206467172,1,2006,2018,,,206467172,1,HIV infection
20656948,206569482,2,F,20111201,20230213,20220331,20230217,EXP,,US-GILEAD-2022-0575369,GILEAD,,46,YR,A,M,Y,104.3,KG,20230217,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Condition aggravated;Emotional distress;Pain;Renal impairment,206569482,OT,,,206569482,1,2006,201209,,,206569482,1,HIV infection
20662386,206623864,4,F,20220121,20230119,20220401,20230130,EXP,,FR-AUROBINDO-AUR-APL-2022-007807,AUROBINDO,,,,A,M,Y,92,KG,20230130,,HP,FR,FR,EFAVIRENZ,Disease recurrence;Drug interaction;Hepatitis C,206623864,OT,,,206623864,2,20210528,20210820,84,DAY,206623864,1,HIV infection
20728954,207289542,2,F,20170720,20230213,20220420,20230217,EXP,,US-GILEAD-2022-0577998,GILEAD,,50,YR,A,M,Y,26.122,KG,20230217,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Emotional distress;Hip fracture;Osteopenia;Osteoporosis;Pain;Rib fracture,207289542,OT,,,207289542,1,2006,201611,,,207289542,1,HIV infection
20728978,207289782,2,F,20131201,20230120,20220420,20230125,EXP,,US-GILEAD-2022-0578499,GILEAD,,49,YR,A,M,Y,74.84,KG,20230125,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Chronic kidney disease;Emotional distress;Pain,207289782,OT,,,207289782,1,2012,201312,,,207289782,1,HIV infection
20729008,207290082,2,F,20130101,20230124,20220420,20230131,EXP,,US-GILEAD-2022-0578505,GILEAD,,,,A,M,Y,120,KG,20230131,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Bone demineralisation;Compression fracture;Emotional distress;Femur fracture;Foot fracture;Hip fracture;Humerus fracture;Osteoporosis;Pain;Rib fracture;Spinal fracture;Upper limb fracture,207290082,OT,,,207290082,1,2006,201710,,,207290082,1,HIV infection
20729777,207297773,3,F,20180101,20230124,20220420,20230130,EXP,,US-GILEAD-2022-0578508,GILEAD,,,,A,M,Y,94.331,KG,20230130,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Pain;Renal impairment,207297773,OT,,,207297773,1,2007,2018,,,207297773,1,HIV infection
20732933,207329332,2,F,20201001,20230109,20220420,20230112,EXP,,US-GILEAD-2022-0578571,GILEAD,,54,YR,A,M,Y,57.143,KG,20230112,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Blood creatinine increased;Chronic kidney disease;Emotional distress;Pain;Renal failure,207329332,OT,,,207329332,1,2016,,,,207329332,1,HIV infection
20733486,207334862,2,F,20170101,20230225,20220421,20230301,EXP,,US-GILEAD-2022-0578540,GILEAD,,,,A,M,Y,116.1,KG,20230301,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Bone demineralisation;Bone loss;Emotional distress;Osteoporosis;Pain;Tooth loss,207334862,OT,,,207334862,1,2004,201809,,,207334862,1,HIV infection
20858432,208584324,4,F,,20230316,20220521,20230323,EXP,,CA-009507513-2205CAN005476,MERCK,,54,YR,,M,Y,,,20230323,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Product use in unapproved indication;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,208584324,HO,,,,,,,,,208584324,1,HIV infection
20858945,208589452,2,F,20040601,20230226,20220522,20230301,EXP,,US-GILEAD-2022-0582563,GILEAD,,50,YR,A,M,Y,100.24,KG,20230301,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Bone loss;Chronic kidney disease;Emotional distress;Femur fracture;Foot fracture;Hypertension;Lymphoma;Multiple fractures;Nephrolithiasis;Osteoporosis;Pain;Radius fracture;Renal impairment;Renal injury,208589452,OT,,,208589452,1,2004,201609,,,208589452,1,HIV infection
20859527,208595273,3,F,20131201,20230218,20220523,20230222,PER,,US-GILEAD-2022-0582524,GILEAD,,48,YR,A,M,Y,,,20230222,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Pain;Renal failure;Renal impairment,208595273,HO,,,208595273,1,2012,201403,,,208595273,1,HIV infection
20859661,208596612,2,F,20160801,20230218,20220523,20230222,PER,,US-GILEAD-2022-0582397,GILEAD,,55,YR,A,M,Y,72.57,KG,20230222,,LW,US,US,SUSTIVA,Abdominal discomfort;Acute kidney injury;Anhedonia;Anxiety;Depression;Emotional distress;Insomnia;Pain;Renal failure;Renal impairment;Tachyphrenia;Urine analysis abnormal,208596612,OT,,,208596612,1,2005,201612,,,208596612,1,HIV infection
20859947,208599472,2,F,20150901,20230215,20220523,20230221,EXP,,US-GILEAD-2022-0582540,GILEAD,,38,YR,A,M,Y,98,KG,20230221,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Hypertension;Pain,208599472,OT,,,208599472,1,2005,201707,,,208599472,1,Product used for unknown indication
20860647,208606472,2,F,20080101,20230220,20220523,20230222,PER,,US-GILEAD-2022-0582512,GILEAD,,,,A,F,Y,68.027,KG,20230222,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Bone demineralisation;Emotional distress;Foot fracture;Hyperlipidaemia;Hypertension;Intervertebral disc degeneration;Osteopenia;Pain;Wrist fracture,208606472,OT,,,208606472,1,2004,201512,,,208606472,1,HIV infection
20864130,208641302,2,F,20100101,20230304,20220523,20230309,EXP,,US-GILEAD-2022-0582593,GILEAD,,,,A,F,Y,64,KG,20230309,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Emotional distress;Hand fracture;Osteopenia;Osteoporosis;Pain;Pneumothorax;Rib fracture;Skeletal injury;Wrist fracture,208641302,HO,,,208641302,1,2006,201806,,,208641302,1,HIV infection
20864139,208641392,2,F,20080101,20230219,20220523,20230223,EXP,,US-GILEAD-2022-0582671,GILEAD,,,,A,M,Y,106.58,KG,20230223,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Hypertension;Nephrolithiasis;Pain,208641392,OT,,,208641392,1,2001,,,,208641392,1,HIV infection
20864227,208642272,2,F,20130101,20230222,20220523,20230224,PER,,US-GILEAD-2022-0582528,GILEAD,,,,A,M,Y,72.5,KG,20230224,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Emotional distress;Pain,208642272,HO,,,208642272,1,2012,2013,,,208642272,1,HIV infection
20868953,208689532,2,F,20040401,20230221,20220524,20230224,EXP,,US-GILEAD-2022-0582604,GILEAD,,44,YR,A,F,Y,,,20230224,,LW,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Blood creatinine increased;Bone demineralisation;Emotional distress;Humerus fracture;Multiple fractures;Osteopenia;Osteoporosis;Pain;Radius fracture;Wrist fracture,208689532,OT,,,208689532,1,2001,201711,,,208689532,1,HIV infection
20869041,208690412,2,F,20161001,20230218,20220524,20230222,EXP,,US-GILEAD-2022-0582682,GILEAD,,55,YR,A,M,Y,88.4,KG,20230222,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Chronic kidney disease;Emotional distress;Osteopenia;Pain,208690412,OT,,,208690412,1,2005,2006,,,208690412,1,HIV infection
20871852,208718529,9,F,,20230308,20220525,20230315,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2022082351,VIIV,,,,,,Y,,,20230315,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,208718529,OT,,,,,,,,,208718529,1,HIV infection
20871865,208718659,9,F,,20230308,20220525,20230315,EXP,,CA-GLAXOSMITHKLINE-CA2022082351,GLAXOSMITHKLINE,,,,,,Y,,,20230315,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,208718659,HO,,,,,,,,,208718659,1,HIV infection
20883079,208830794,4,F,,20230308,20220527,20230314,EXP,,CA-BAUSCH-BL-2022-012991,BAUSCH AND LOMB,,54,YR,,M,Y,,,20230314,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,208830794,OT,,,,,,,,,208830794,1,Depression
20884066,208840666,6,F,,20230320,20220527,20230329,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2022GSK084848,VIIV,,,,,,Y,,,20230329,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Incorrect route of product administration;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose;Product use in unapproved indication,208840666,DE,,,,,,,,,208840666,1,HIV infection
20884074,208840746,6,F,,20230320,20220527,20230329,EXP,,CA-GLAXOSMITHKLINE-CA2022GSK084848,GLAXOSMITHKLINE,,,,,,Y,,,20230329,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Incorrect route of product administration;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose;Product use in unapproved indication,208840746,OT,,,,,,,,,208840746,1,HIV infection
20892665,208926654,4,F,,20230302,20220531,20230308,EXP,,CA-ABBVIE-22K-028-4414704-00,ABBVIE,,54,YR,,M,Y,,,20230308,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Product use in unapproved indication;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,208926654,HO,,,,,,,,,208926654,1,Bipolar disorder
20898424,2089842439,39,F,20180205,20221125,20220601,20230112,EXP,GB-EMA-DD-20190508-sahu_k-153427,GB-ABBVIE-22K-167-4414502-00,ABBVIE,,43,YR,,F,Y,43,KG,20230112,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Intentional product use issue;Maternal exposure during pregnancy;Off label use,2089842439,CA,,,2089842439,1,20100610,20180205,122,DAY,2089842439,1,HIV infection
20945155,2094515525,25,F,20100629,20230314,20220610,20230324,EXP,,GB-EMD Serono-E2B_90051865,EMD SERONO INC,,43,YR,A,F,Y,43,KG,20230324,,HP,GB,,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Caesarean section;Drug abuse;Exposure during pregnancy;Hepatic cytolysis;Intentional product use issue;Maternal exposure during pregnancy;Off label use;Ultrasound antenatal screen,2094515525,OT,,,2094515525,7,20100610,20100610,1,DAY,2094515525,1,Product used for unknown indication
20966864,209668642,2,F,,20220609,20220616,20230113,EXP,,DK-STRIDES ARCOLAB LIMITED-2022SP007262,STRIDES,"Gulden T, Yahyavi SK, Lodding IP, Jensen J-EB, Blomberg Jensen M.. Severe hypocalcemia due to hypoparathyroidism associated with HIV: A case report.. Bone-Rep.. 2021",67,YR,,M,Y,,,20230109,,HP,DK,DK,EFAVIRENZ,Acute kidney injury;Dehydration;Diarrhoea;Gait disturbance;Hypocalcaemia;Myalgia;Nausea;Vomiting,209668642,HO,,,,,,,,,209668642,1,HIV infection
20969211,2096921145,45,F,20100629,20221125,20220616,20230120,EXP,,GB-ABBVIE-22K-167-4434184-00,ABBVIE,,3,MON,,M,Y,,,20230120,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Caesarean section;Cleft lip and palate;Exposure during pregnancy;Foetal exposure during pregnancy;Hepatic cytolysis;Hydrops foetalis;Intentional product use issue;Maternal exposure during pregnancy;Off label use;Trisomy 18;Ultrasound antenatal screen,2096921145,DE,,,2096921145,2,20100610,20180205,123,DAY,2096921145,1,Maternal exposure timing unspecified
20993425,209934254,4,F,,20230215,20220622,20230222,EXP,,CA-JNJFOC-20220629261,JOHNSON AND JOHNSON,,54,YR,A,M,Y,,,20230222,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,209934254,HO,,,,,,,,,209934254,1,Depression
21007036,2100703625,25,F,20120521,20230217,20220625,20230227,EXP,GB-EMA-DD-20180827-KSEVHUMANWT-124609,GB-Accord-109343,ACCORD,,3,MON,I,M,Y,,,20230227,,HP,GB,GB,EFAVIRENZ,Alanine aminotransferase increased;Aspartate aminotransferase increased;Cleft lip and palate;Foetal exposure during pregnancy;Hepatic cytolysis;Hydrops foetalis;Intentional product use issue;Trisomy 18;Ultrasound antenatal screen,2100703625,DE,,,2100703625,1,20100610,20180205,4,MON,,,
21021504,2102150428,28,F,20100629,20230109,20220629,20230118,EXP,,GB-HORMOSAN PHARMA GMBH-2022-08992,LUPIN,,16,WK,,M,Y,,,20230118,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Caesarean section;Cleft lip and palate;Foetal exposure during pregnancy;Hepatic cytolysis;Hydrops foetalis;Intentional product use issue;Off label use;Trisomy 18;Ultrasound antenatal screen,2102150428,DE,,,2102150428,1,20171006,20180205,4,MON,2102150428,1,HIV infection
21039057,2103905713,13,F,20120521,20230214,20220704,20230227,EXP,,GB-CIPLA LTD.-2022GB04083,CIPLA,,,,,,Y,,,20230227,,MD,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Hepatic cytolysis,2103905713,CA,,,2103905713,2,20100610,20180205,122,DAY,2103905713,1,HIV infection
21124310,2112431020,20,F,20120521,20230209,20220725,20230223,EXP,,GB-CIPLA LTD.-2022GB04466,CIPLA,,,,,,Y,,,20230223,,MD,GB,GB,EFAVIRENZ,Alanine aminotransferase increased;Aspartate aminotransferase increased;Cleft lip and palate;Foetal exposure during pregnancy;Hepatic cytolysis;Hydrops foetalis;Intentional product use issue;Off label use;Trisomy 18;Ultrasound antenatal screen,2112431020,OT,,,,,,,,,,,
21141067,211410672,2,F,20060701,20220725,20220728,20230323,EXP,,PT-GILEAD-2022-0591091,GILEAD,,54,YR,A,M,Y,,,20230322,,MD,PT,PT,EFAVIRENZ,Adverse drug reaction;Drug ineffective;Pneumocystis jirovecii pneumonia;Rash,211410672,OT,,,211410672,1,200607,200504,,,211410672,1,HIV infection
21158239,211582392,2,F,20060701,20220725,20220801,20230327,EXP,,PT-VIIV HEALTHCARE LIMITED-PT2022112005,VIIV,,,,,,Y,,,20230327,,MD,PT,PT,EFAVIRENZ,Adverse drug reaction;Drug ineffective;Pneumocystis jirovecii pneumonia;Rash,211582392,OT,,,211582392,1,200607,200504,,,211582392,1,HIV infection
21158241,211582412,2,F,20060701,20220725,20220801,20230327,EXP,,PT-GSK-PT2022112005,GLAXOSMITHKLINE,,,,,,Y,,,20230327,,MD,PT,PT,EFAVIRENZ,Adverse drug reaction;Drug ineffective;Pneumocystis jirovecii pneumonia;Rash,211582412,OT,,,211582412,1,200607,200504,,,211582412,1,HIV infection
21166263,211662632,2,F,,20230113,20220803,20230120,EXP,,CA-AstraZeneca-2022A267561,ASTRAZENECA,,54,YR,,M,Y,,,20230120,,MD,CA,,SUSTIVA,Depression;Drug interaction,211662632,OT,,,,,,,,,211662632,1,Product used for unknown indication
21193670,211936702,2,F,,20230103,20220810,20230105,EXP,,CA-009507513-2208CAN003680,MERCK,,,,,M,Y,,,20230105,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction,211936702,HO,,,,,,,,,211936702,1,Product used for unknown indication
21220860,212208604,4,F,20200801,20230202,20220817,20230210,EXP,,DK-AUROBINDO-AUR-APL-2022-032254,AUROBINDO,"Mens H, Fjordside L, Fonager J, Gerstoft J.. Emergence of the G118R Pan-Integrase Resistance Mutation as a Result of Low Compliance to a Dolutegravir-Based cART. Infectious Disease Reports.. 2022;14(4):501-504.",50,YR,,M,Y,,,20230210,,HP,DK,DK,EFAVIRENZ,Multiple-drug resistance;Pathogen resistance;Treatment failure;Treatment noncompliance;Viral mutation identified;Virologic failure,212208604,OT,,,,,,,,,212208604,1,HIV infection
21238262,212382622,2,F,,20230124,20220822,20230202,EXP,,IT-MYLANLABS-2022M1087630,MYLAN,"Calcagno A, Celani L, Trunfio M, Orofino G, Imperiale D, Atzori C, et al. Alzheimer Dementia in People Living With HIV. Neurol-Clin-Pract 2021;11(5):E627-E633.",71,YR,,M,Y,,,20230202,,MD,IT,IT,EFAVIRENZ,Dementia Alzheimer's type,212382622,OT,,,,,,,,,212382622,1,HIV infection
21364311,213643112,2,F,,20230124,20220922,20230201,EXP,,DK-MYLANLABS-2022M1095642,MYLAN,"Mens H, Fjordside L, Fonager J, Gerstoft J. Emergence of the G118R Pan-Integrase Resistance Mutation as a Result of Low Compliance to a Dolutegravir-Based cART. Infect-Dis-Rep 2022;14(4):501-504.",50,YR,,M,Y,,,20230201,,HP,DK,DK,EFAVIRENZ,Multiple-drug resistance,213643112,OT,,,,,,,,,213643112,1,HIV infection
21383725,213837253,3,F,,20221011,20220928,20230113,EXP,,IN-STRIDES ARCOLAB LIMITED-2022SP012269,STRIDES,,,,,,Y,,,20230109,,HP,IN,IN,EFAVIRENZ,Anencephaly;Foetal exposure during pregnancy;Neural tube defect;Spina bifida,213837253,OT,,,,,,,,,213837253,1,Product used for unknown indication
21395180,213951805,5,F,20100629,20230131,20220930,20230209,EXP,,GB-AUROBINDO-AUR-APL-2022-021223,AUROBINDO,,43,YR,,F,Y,43,KG,20230209,,MD,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Caesarean section;Cleft lip and palate;Drug abuse;Exposure during pregnancy;Hepatic cytolysis;Hydrops foetalis;Intentional product use issue;Maternal exposure during pregnancy;Off label use;Trisomy 18;Ultrasound antenatal screen,213951805,CA,,,213951805,1,20171006,20180205,4,MON,213951805,1,HIV infection
21395959,2139595910,10,F,20120521,20230208,20220930,20230220,EXP,,NVSC2018GB021924,NOVARTIS,,43,YR,,F,Y,,,20230220,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Drug abuse;Hepatic cytolysis;Intentional product use issue;Maternal exposure during pregnancy;Off label use;Ultrasound antenatal screen,2139595910,CA,,,2139595910,3,20100610,20180205,4,MON,2139595910,1,Product used for unknown indication
21411803,214118035,5,F,,20230302,20221005,20230317,EXP,,CA-MYLANLABS-2022M1110802,MYLAN,,54,YR,,M,Y,,,20230317,,HP,CA,CA,EFAVIRENZ,Anxiety;Depression suicidal;Depressive symptom;Drug interaction;Off label use;Paranoia;Product use in unapproved indication;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,214118035,OT,,,214118035,1,2007,,,,214118035,1,Bipolar disorder
21549976,215499763,3,F,,20230203,20221103,20230213,EXP,,PL-BRISTOL-MYERS SQUIBB COMPANY-2022-128597,BRISTOL MYERS SQUIBB,"Aksak-Was BJ, Leszczyszyn-Pynka M, Parczewski M, Krzysztalowski A. Interdisciplinary management of multidrug-resistant tuberculosis in an HIV-infected patient: case report. HIV and AIDS Review. 2017 Oct 13; 16(3): 198-203.doi:10.5114/hivar.2017.70947.",43,YR,A,M,Y,,,20230213,,HP,PL,PL,EFAVIRENZ,Blood bilirubin increased;Clostridium difficile colitis;Conductive deafness;Diarrhoea;Drug ineffective;Drug resistance;Hepatitis cholestatic;Lymphopenia;Myalgia;Nausea;Neuropsychiatric symptoms;Neutropenia;Pancreatitis;Pathogen resistance;Urinary tract infection;Urinary tract inflammation,215499763,HO,,,215499763,1,2011,,,,215499763,1,Acquired immunodeficiency syndrome
21557464,215574642,2,F,20110101,20230203,20221105,20230211,EXP,,PL-AUROBINDO-AUR-APL-2022-046649,AUROBINDO,"Aksak-Was BJ, Leszczyszyn-Pynka M, Parczewski M, Krzysztalowski A.. Interdisciplinary management of multidrug-resistant tuberculosis in an HIV-infected patient: Case report.. HIV-AIDSRev. 2017;16(3):198-203",43,YR,,M,Y,,,20230211,,MD,PL,PL,EFAVIRENZ,Blood bilirubin increased;Conductive deafness;Diarrhoea;Drug ineffective;Drug resistance;Enterobacter infection;Hepatitis cholestatic;Lymphopenia;Myalgia;Nausea;Neuropsychiatric symptoms;Neutropenia;Pancreatitis,215574642,HO,,,215574642,14,201104,,,,215574642,1,Enterobacter infection
21557666,215576664,4,F,20120101,20230208,20221106,20230216,EXP,,PL-JNJFOC-20221056107,JOHNSON AND JOHNSON,,43,YR,A,M,Y,,,20230216,,HP,PL,PL,EFAVIRENZ,Clostridium difficile colitis;Diarrhoea;Drug resistance;Hepatitis cholestatic;Lymphopenia;Myalgia;Nausea;Neuropsychiatric symptoms;Neutropenia;Pancreatitis;Pathogen resistance;Urinary tract infection;Urinary tract inflammation,215576664,OT,,,215576664,2,2011,,,,215576664,1,Acquired immunodeficiency syndrome
21577560,215775602,2,F,,20230124,20221110,20230201,EXP,,IT-MYLANLABS-2022M1122353,MYLAN,"Calcagno A, Celani L, Trunfio M, Orofino G, Imperiale D, Atzori C, et al. Alzheimer Dementia in People Living With HIV. Neurol-Clin-Pract. 2021;11(5):E627-E633",71,YR,,M,Y,,,20230201,,MD,IT,IT,EFAVIRENZ,Dementia Alzheimer's type,215775602,OT,,,,,,,,,215775602,1,HIV infection
21583026,215830262,2,F,,20221230,20221111,20230110,EXP,CA-MHPD-E2B_05617673,CA-Accord-284705,ACCORD,,54,YR,A,M,Y,,,20230110,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,215830262,HO,,,,,,,,,215830262,1,Depression
21602270,216022707,7,F,,20230206,20221116,20230213,EXP,,NVSC2022PL256627,NOVARTIS,"Aksak-Was BJ, Leszczyszyn-Pynka M, Parczewski M, Krzysztalowski A. Interdisciplinary management of multidrug-resistant tuberculosis in an HIV-infected patient: Case report. HIV AND AIDS REVIEW. 2017;16(3):198-203",43,YR,,M,Y,,,20230213,,HP,PL,PL,EFAVIRENZ,Clostridium difficile colitis;Diarrhoea;Drug resistance;Hepatitis cholestatic;Lymphopenia;Myalgia;Nausea;Neuropsychiatric symptoms;Neutropenia;Pancreatitis;Pathogen resistance;Urinary tract infection;Urinary tract inflammation,216022707,OT,,,216022707,11,2011,,,,216022707,1,Toxoplasmosis
21606753,216067534,4,F,,20221212,20221117,20230201,EXP,,PL-GILEAD-2022-0603189,GILEAD,,43,YR,A,M,Y,,,20230201,,HP,PL,PL,EFAVIRENZ,Blood bilirubin increased;Clostridium difficile colitis;Conductive deafness;Diarrhoea;Drug ineffective;Drug resistance;Hepatitis cholestatic;Lymphopenia;Myalgia;Nausea;Neuropsychiatric symptoms;Neutropenia;Pancreatitis;Pathogen resistance;Urinary tract infection;Urinary tract inflammation,216067534,HO,,,216067534,4,2011,,,,216067534,1,HIV infection
21615178,216151782,2,F,,20230227,20221118,20230306,EXP,,KE-VIIV HEALTHCARE LIMITED-KE2022GSK165931,VIIV,"Koech MK, Ali SM, Karoney MJ, Kigen G. Severe abacavir hypersensitivity reaction in a patient with human immunodeficiency virus infection: a case report. Journal of medical case reports.. 2022;16(1):407",,,,,Y,,,20230306,,HP,KE,KE,EFAVIRENZ,Abdominal discomfort;Abdominal pain;Abdominal tenderness;Acute kidney injury;Blood HIV RNA increased;Chest discomfort;Chest pain;Chills;Confusional state;Conversion disorder;Cough;Decreased appetite;Diarrhoea;Generalised oedema;Headache;Hepatic function abnormal;Hepatitis viral;Hyperhidrosis;Hypersensitivity;Hypotension;Intentional product misuse;Malaise;Myalgia;Nausea;Neuropathy peripheral;Nosocomial infection;Oropharyngeal pain;Pain;Palpitations;Paraesthesia;Pharyngeal inflammation;Pharyngitis;Pyrexia;Rash;Respiratory alkalosis;Self-medication;Stomatitis;Tachycardia;Virologic failure;Vomiting,216151782,HO,,,216151782,8,,,2,MON,216151782,1,HIV infection
21652667,216526673,3,F,,20230118,20221128,20230123,EXP,,CA-MYLANLABS-2022M1132690,MYLAN,,52,YR,,M,Y,,,20230123,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,216526673,OT,,,,,,,,,216526673,1,HIV infection
21670133,216701332,2,F,,20230320,20221201,20230327,EXP,,CA-BAUSCH-BL-2022-026430,BAUSCH AND LOMB,,54,YR,,M,Y,,,20230327,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose,216701332,DE,,,,,,,,,216701332,1,Bipolar disorder
21699720,216997202,2,F,20200801,20230124,20221208,20230207,EXP,,DK-MYLANLABS-2022M1135462,MYLAN,"Mens H, Fjordside L, Fonager J, Gerstoft J... Resistance Mutation as a Result of Low Compliance to a Dolutegravir-Based cART.. Emergence of the G118R Pan-Integrase.. 2022;14 (4):501-504",50,YR,,M,Y,,,20230207,,HP,DK,DK,EFAVIRENZ,Multiple-drug resistance;Pathogen resistance;Treatment failure;Treatment noncompliance;Viral mutation identified;Virologic failure,216997202,OT,,,,,,,,,216997202,1,HIV infection
21787127,217871273,3,F,,20230310,20221228,20230321,EXP,,ES-AUROBINDO-AUR-APL-2022-054940,AUROBINDO,"Holguin A, Ventosa-Cubillo J, Pinzon R, Gonzalez-Alba JM, Estripeaut D, Navarro ML.. Drug resistance in children and adolescents with HIV in Panama. The Journal of antimicrobial chemotherapy. 2023;78:423-435",15,YR,,,Y,,,20230321,,HP,ES,ES,EFAVIRENZ,HIV viraemia;Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,217871273,OT,,,,,,,,,217871273,1,Perinatal HIV infection
21807743,218077431,1,I,,20221220,20230103,20230103,EXP,,CA-AUROBINDO-AUR-APL-2022-056016,AUROBINDO,,63,YR,,F,Y,,,20230103,,CN,CA,CA,EFAVIRENZ,Alanine aminotransferase increased;Diarrhoea;Fatigue;Liver disorder;Low density lipoprotein increased;Mouth ulceration;Nausea;Nephrolithiasis;Osteoporosis;Renal disorder;Sleep terror;Type 2 diabetes mellitus,218077431,OT,,,,,,,,,218077431,1,HIV infection
21812941,218129411,1,I,20220101,20221226,20230103,20230103,EXP,,BY-MYLANLABS-2022M1148509,MYLAN,Gvozdeliuk V O. BONE MINERAL DENSITY IN PATIENTS WITH HIV INFECTION,68,YR,,F,Y,,,20230103,,HP,BY,BY,EFAVIRENZ,Osteoporosis,218129411,DS,,,218129411,1,2017,,,,218129411,1,HIV infection
21815433,218154331,1,I,,20221221,20230104,20230104,EXP,,NL-AUROBINDO-AUR-APL-2022-056564,AUROBINDO,"Gordijn R, Wessels W, Kriek E, Nicolai P J M, Elzevier W H,Visser L et al.. Patient reporting of sexual adverse events onan online platform for medication experiences.. BritishJournal of Clinical Pharmacology.. 2022;88(12):5326-5335",,,,M,Y,,,20230104,,HP,NL,NL,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Sexual dysfunction,218154331,OT,,,,,,,,,218154331,1,Product used for unknown indication
21816784,218167841,1,I,,20221228,20230104,20230104,EXP,,NA-VIIV HEALTHCARE LIMITED-NA2022GSK193544,VIIV,"Kakubu MAM, Frans K, Gibutai N, Katoto PD. A case report of clinical implications of a delayed antiretroviral therapy switch in a patient with multiple treatment interruptions. SAGE Open Medical Case Reports. 2022;10",,,,,Y,,,20230104,,HP,,,EFAVIRENZ,Acquired immunodeficiency syndrome;Disease recurrence;Immunosuppression;Malaise;Oesophageal candidiasis;Treatment noncompliance;Virologic failure,218167841,OT,,,218167841,1,20150129,20170406,210,DAY,218167841,1,HIV infection
21816785,218167851,1,I,,20221228,20230104,20230104,EXP,,NA-GSK-NA2022GSK193544,GLAXOSMITHKLINE,"Kakubu MAM, Frans K, Gibutai N, Katoto PD. A case report of clinical implications of a delayed antiretroviral therapy switch in a patient with multiple treatment interruptions. SAGE Open Medical Case Reports. 2022;10",,,,,Y,,,20230104,,HP,,,EFAVIRENZ,Acquired immunodeficiency syndrome;Disease recurrence;Immunosuppression;Malaise;Oesophageal candidiasis;Treatment noncompliance;Virologic failure,218167851,OT,,,218167851,1,20150129,20170406,210,DAY,218167851,1,HIV infection
21818777,218187771,1,I,,20221228,20230104,20230104,EXP,,BE-MYLANLABS-2022M1148482,MYLAN,"Gonzaga LDM, Gils T, Decroo T, Jacobs BKM, Lynen L. Case report: Therapeutic threshold for rifampicin-resistant tuberculosis in a patient from Maputo, Mozambique. Am-J-Trop-Med-Hyg. 2021;104(4):1317-1320",40,YR,,F,Y,,,20230104,,HP,BE,BE,EFAVIRENZ,Treatment failure,218187771,OT,,,218187771,1,2018,,,,218187771,1,Tuberculosis
21819252,218192522,2,F,,20230320,20230104,20230321,EXP,,CA-BAUSCH-BL-2023-000057,BAUSCH AND LOMB,,,,,M,Y,,,20230321,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,218192522,HO,,,,,,,,,218192522,1,Product used for unknown indication
21819256,218192561,1,I,,20230102,20230104,20230104,EXP,,CA-BAUSCH-BL-2023-000064,BAUSCH AND LOMB,,54,YR,,M,Y,,,20230104,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,218192561,OT,,,,,,,,,218192561,1,Product used for unknown indication
21819259,218192591,1,I,,20230102,20230104,20230104,EXP,,CA-BAUSCH-BL-2023-000083,BAUSCH AND LOMB,,54,YR,,M,Y,,,20230104,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,218192591,OT,,,,,,,,,218192591,1,Bipolar disorder
21819262,218192621,1,I,,20230102,20230104,20230104,EXP,,CA-BAUSCH-BL-2023-000074,BAUSCH AND LOMB,,54,YR,,M,Y,,,20230104,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,218192621,HO,,,,,,,,,218192621,1,Depression
21819264,218192641,1,I,,20230102,20230104,20230104,EXP,,CA-BAUSCH-BL-2023-000080,BAUSCH AND LOMB,,44,YR,,M,Y,,,20230104,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,218192641,HO,,,,,,,,,218192641,1,Depression
21820307,218203071,1,I,,20221228,20230105,20230105,EXP,,IN-STRIDES ARCOLAB LIMITED-2023SP000095,STRIDES,"Sivagourounadin K, Rajendran P, Selvarajan S, Ganesapandian M.. Agreement Among Different Scales for Causality Assessment in Drug-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.. Curr-Drug-Saf. 2022;17(1):40-46.",44,YR,,F,Y,,,20230105,,HP,IN,IN,EFAVIRENZ,Off label use;SJS-TEN overlap,218203071,OT,,,218203071,1,,,30,DAY,218203071,1,Acquired immunodeficiency syndrome
21820995,218209951,1,I,,20221216,20230105,20230105,EXP,,GB-HORMOSAN PHARMA GMBH-2022-14663,LUPIN,,,,,M,Y,,,20221227,,HP,GB,GB,EFAVIRENZ,Death,218209951,DE,,,,,,,,,218209951,1,Product used for unknown indication
21822389,218223891,1,I,20220110,20230101,20230105,20230105,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2023EME000250,VIIV,,,,,,Y,,,20230105,,MD,FR,FR,EFAVIRENZ,Pathogen resistance;Treatment noncompliance;Viral mutation identified,218223891,OT,,,218223891,1,20220101,,,,218223891,1,HIV infection
21822400,218224001,1,I,20220110,20230101,20230105,20230105,EXP,,FR-GSK-FR2023EME000250,GLAXOSMITHKLINE,,,,,,Y,,,20230105,,MD,FR,FR,EFAVIRENZ,Pathogen resistance;Treatment noncompliance;Viral mutation identified,218224001,OT,,,218224001,1,20220101,,,,218224001,1,HIV infection
21830307,218303071,1,I,,20221228,20230106,20230106,EXP,,IN-MYLANLABS-2022M1141448,MYLAN,"Sivagourounadin K, Rajendran P, Selvarajan S, Ganesapandian M. Agreement Among Different Scales for Causality Assessment in Drug-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Curr-Drug-Saf 2022;17(1):40-46.",44,YR,,F,Y,,,20230106,,HP,IN,IN,EFAVIRENZ,SJS-TEN overlap,218303071,OT,,,,,,,,,218303071,1,Acquired immunodeficiency syndrome
21830862,218308621,1,I,,20230102,20230106,20230106,EXP,,ES-GSK-ES2023GSK000216,GLAXOSMITHKLINE,"Gil H, Delgado E, Benito S, Moreno-Lorenzo M, Thomson MM. Factors associated with HIV-1 resistance to integrase strand transfer inhibitors in Spain: Implications for dolutegravir-containing regimens. Frontiers in Microbiology. 2022;13",,,,,Y,,,20230106,,HP,ES,ES,EFAVIRENZ,Pathogen resistance;Treatment noncompliance;Viral mutation identified,218308621,OT,,,,,,,,,218308621,1,HIV infection
21830863,218308631,1,I,,20230102,20230106,20230106,EXP,,ES-GSK-ES2023GSK000520,GLAXOSMITHKLINE,"Gil H, Delgado E, Benito S, Moreno-Lorenzo M, Thomson MM. Factors associated with HIV-1 resistance to integrase strand transfer inhibitors in Spain: Implications for dolutegravir-containing regimens. Frontiers in Microbiology. 2022;13",,,,,Y,,,20230106,,HP,ES,ES,EFAVIRENZ,Pathogen resistance;Treatment noncompliance;Viral mutation identified,218308631,OT,,,,,,,,,218308631,1,HIV infection
21830867,218308671,1,I,,20230102,20230106,20230106,EXP,,ES-VIIV HEALTHCARE LIMITED-ES2023GSK000216,VIIV,"Gil H, Delgado E, Benito S, Moreno-Lorenzo M, Thomson MM. Factors associated with HIV-1 resistance to integrase strand transfer inhibitors in Spain: Implications for dolutegravir-containing regimens. Frontiers in Microbiology. 2022;13",,,,,Y,,,20230106,,HP,ES,ES,EFAVIRENZ,Pathogen resistance;Treatment noncompliance;Viral mutation identified,218308671,OT,,,,,,,,,218308671,1,HIV infection
21830869,218308691,1,I,,20230102,20230106,20230106,EXP,,ES-VIIV HEALTHCARE LIMITED-ES2023GSK000520,VIIV,"Gil H, Delgado E, Benito S, Moreno-Lorenzo M, Thomson MM. Factors associated with HIV-1 resistance to integrase strand transfer inhibitors in Spain: Implications for dolutegravir-containing regimens. Frontiers in Microbiology. 2022;13",,,,,Y,,,20230106,,HP,ES,ES,EFAVIRENZ,Pathogen resistance;Treatment noncompliance;Viral mutation identified,218308691,OT,,,,,,,,,218308691,1,HIV infection
21838351,218383511,1,I,,20221230,20230109,20230109,EXP,,CA-TEVA-2023-CA-2842697,TEVA,,63,YR,A,F,Y,,,20230109,,CN,CA,CA,EFAVIRENZ,Alanine aminotransferase increased;Diarrhoea;Fatigue;Liver disorder;Low density lipoprotein increased;Mouth ulceration;Nausea;Nephrolithiasis;Osteoporosis;Renal disorder;Sleep terror;Type 2 diabetes mellitus,218383511,OT,,,,,,,,,218383511,1,HIV infection
21838893,218388931,1,I,,20170710,20230109,20230109,EXP,,IN-HETERO-2017HINLIT0642,HETERO,"Amrutha PC, Rakesh TP, Kidangazhiyathmana A, Chakkunny SC, Rewari BB, Andrews AM.. The enigma of lamivudine rash: Experience on re?challenge from an anti retroviral treatment center in South India.. Indian-J-Dermatol-Venereol-Leprol. 2017;83(4):502-504",48,YR,,F,Y,,,20230109,,MD,IN,IN,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Anaemia;Drug reaction with eosinophilia and systemic symptoms;Oral disorder;Rash,218388931,OT,,,,,,,,,218388931,1,HIV infection
21841940,218419402,2,F,20190101,20230215,20230110,20230227,EXP,,NA-CIPLA LTD.-2023NA00060,CIPLA,"Mpalang Kakubu MA, Frans K, Gibutai N, Katoto PDMC. A case report of clinical implications of a delayed antiretroviral therapy switch in a patient with multiple treatment interruptions. SAGE Open Medical Case Reports. 2022;10:1 to 4",,,,,Y,,,20230227,,HP,,,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Treatment noncompliance;Virologic failure,218419402,OT,,,218419402,1,20150129,20170406,,,218419402,1,HIV infection WHO clinical stage I
21844827,218448272,2,F,,20230112,20230110,20230119,EXP,,US-GILEAD-2023-0611873,GILEAD,,,,A,F,Y,,,20230119,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Depression;Emotional distress;Osteoporosis;Pain,218448272,OT,,,218448272,1,2011,201812,,,218448272,1,HIV infection
21844921,218449212,2,F,20150101,20230202,20230110,20230207,EXP,,US-GILEAD-2023-0611880,GILEAD,,,,A,M,Y,,,20230207,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Chronic kidney disease;Depression;Emotional distress;Osteoporosis;Pain;Renal failure;Wrist fracture,218449212,OT,,,218449212,1,2012,201511,,,218449212,1,HIV infection
21849306,218493061,1,I,20220110,20230109,20230111,20230111,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-2023-004508,BRISTOL MYERS SQUIBB,,41,YR,A,F,Y,,,20230111,,CN,FR,FR,EFAVIRENZ,Pathogen resistance;Treatment noncompliance;Viral mutation identified,218493061,OT,,,218493061,1,20220101,,,,218493061,1,HIV infection
21864157,218641572,2,F,,20230110,20230116,20230120,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2023-004599,BRISTOL MYERS SQUIBB,,44,YR,A,M,Y,,,20230120,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Hospitalisation;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,218641572,OT,,,,,,,,,218641572,1,HIV infection
21865382,218653821,1,I,,20230102,20230116,20230116,EXP,,US-CIPLA LTD.-2023US00123,CIPLA,"Horner MJ, Hazra R, Barnholtz-Sloan JS, Shiels MS, Engels EA. Cancer risk among HIV-exposed uninfected children in the United States. AIDS",,,,F,Y,,,20230116,,HP,US,US,EFAVIRENZ,Ependymoma;Foetal exposure during pregnancy,218653821,OT,,,,,,,,,,,
21867159,218671591,1,I,,20230104,20230116,20230116,EXP,,US-CIPLA LTD.-2023US00170,CIPLA,"Good BL, Fulco PP, Gomes DC,. An unexpected interaction between warfarin and cobicistat-boosted elvitegravir. AIDS. 2015;29 (8):985 to 986",42,YR,,M,Y,,,20230116,,HP,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Anticoagulation drug level below therapeutic;Drug interaction;Dysphoria,218671591,OT,,,,,,,,,218671591,1,HIV infection
21878572,218785721,1,I,,20221213,20230118,20230118,PER,,US-CIPLA LTD.-2022US07389,CIPLA,,45,YR,,F,Y,,,20230118,,HP,US,US,EFAVIRENZ,Exposure during pregnancy;No adverse event,,,,,,,,,,,218785721,1,Antiretroviral therapy
21878649,218786491,1,I,,20230112,20230118,20230118,EXP,,ZA-GSK-ZA2023GSK004630,GLAXOSMITHKLINE,"Botha JC, Steegen K, Edoo M, Nel J, van Zyl GU. Low-level viraemia despite emergence of dolutegravir-resistant variants. Southern African Journal of HIV Medicine. 2022;23 (1)",,,,,Y,,,20230118,,HP,ZA,ZA,EFAVIRENZ,Blood HIV RNA increased;Pathogen resistance;Treatment noncompliance;Viraemia;Viral mutation identified;Virologic failure,218786491,OT,,,218786491,1,2015,2015,,,218786491,1,HIV infection
21878650,218786501,1,I,,20230112,20230118,20230118,EXP,,ZA-VIIV HEALTHCARE LIMITED-ZA2023GSK004630,VIIV,"Botha JC, Steegen K, Edoo M, Nel J, van Zyl GU. Low-level viraemia despite emergence of dolutegravir-resistant variants. Southern African Journal of HIV Medicine. 2022;23 (1)",,,,,Y,,,20230118,,HP,ZA,ZA,EFAVIRENZ,Blood HIV RNA increased;Pathogen resistance;Treatment noncompliance;Viraemia;Viral mutation identified;Virologic failure,218786501,OT,,,218786501,1,2015,2015,,,218786501,1,HIV infection
21881778,218817781,1,I,20220110,20230107,20230119,20230119,EXP,,FR-AUROBINDO-AUR-APL-2023-001519,AUROBINDO,,41,YR,,F,Y,,,20230119,,MD,FR,FR,EFAVIRENZ,Pathogen resistance;Treatment noncompliance;Viral mutation identified,218817781,OT,,,218817781,1,20220101,,,,218817781,1,HIV infection
21881972,218819721,1,I,,20230107,20230119,20230119,EXP,,ES-AUROBINDO-AUR-APL-2023-001536,AUROBINDO,"Gil H, Delgado E, Benito S, Moreno-Lorenzo M, Thomson MM. Factors associated with HIV-1 resistance to integrase strand transfer inhibitors in Spain: Implications for dolutegravir-containing regimens.. Frontiers in Microbiology. 2022;13",18,YR,,F,Y,,,20230119,,HP,ES,ES,EFAVIRENZ,Pathogen resistance;Treatment noncompliance;Viral mutation identified,218819721,OT,,,,,,,,,218819721,1,HIV infection
21882800,218828001,1,I,,20230107,20230119,20230119,EXP,,ES-AUROBINDO-AUR-APL-2023-001530,AUROBINDO,"Gil H, Delgado E, Benito S, Moreno-Lorenzo M, Thomson MM.. Factors associated with HIV-1 resistance to integrase strand transfer inhibitors in Spain: Implications for dolutegravir-containing regimens.. Frontiers in Microbiology. 2022;13",31,YR,,M,Y,,,20230119,,HP,ES,ES,EFAVIRENZ,Pathogen resistance;Treatment noncompliance;Viral mutation identified,218828001,OT,,,,,,,,,218828001,1,HIV infection
21884801,218848011,1,I,,20230113,20230119,20230119,EXP,,ZW-MYLANLABS-2023M1006169,MYLAN,"Mutambanengwe-Jacob MT, Maponga CC, Amico KR, Ngara B, Yende-Zuma N, Chawana TD, et al. Impact of Motivational Enhanced Adherence Counseling and Point-of-Care Viral Load Monitoring on Viral Load Outcome in Women on Life-Long ART: A Randomized Pilot Study. AIDS-Res-Treat 2022;null:null.",,,,F,Y,,,20230119,,HP,ZW,ZW,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Virologic failure,218848011,OT,,,,,,,,,218848011,1,HIV infection
21886790,218867901,1,I,,20230113,20230119,20230119,EXP,,ZW-MYLANLABS-2023M1006177,MYLAN,"Mutambanengwe-Jacob MT, Maponga CC, Amico KR, Ngara B, Yende-Zuma N, Chawana TD, et al. Impact of Motivational Enhanced Adherence Counseling and Point-of-Care Viral Load Monitoring on Viral Load Outcome in Women on Life-Long ART: A Randomized Pilot Study. AIDS-Res-Treat 2022;null:null.",,,,F,Y,,,20230119,,HP,ZW,ZW,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Virologic failure,218867901,OT,,,,,,,,,218867901,1,HIV infection
21886792,218867921,1,I,,20230113,20230119,20230119,EXP,,ZW-MYLANLABS-2023M1006176,MYLAN,"Mutambanengwe-Jacob MT, Maponga CC, Amico KR, Ngara B, Yende-Zuma N, Chawana TD, et al. Impact of Motivational Enhanced Adherence Counseling and Point-of-Care Viral Load Monitoring on Viral Load Outcome in Women on Life-Long ART: A Randomized Pilot Study. AIDS-Res-Treat 2022;null:null.",,,,F,Y,,,20230119,,HP,ZW,ZW,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Virologic failure,218867921,OT,,,,,,,,,218867921,1,HIV infection
21889491,218894911,1,I,20230108,20230109,20230120,20230120,EXP,,IN-CIPLA LTD.-2023IN00246,CIPLA,,,,,M,Y,,,20230120,,CN,IN,IN,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Dizziness;Hangover;Nausea;Off label use;Product use in unapproved indication;Syncope,218894911,OT,,,218894911,1,20230108,,,,218894911,1,Prophylaxis against HIV infection
21898448,218984483,3,F,,20230317,20230123,20230323,EXP,,ES-MYLANLABS-2023M1006058,MYLAN,"Ventosa-Cubillo J, Pinzon R, Gonzalez-Alba JM, Estripeaut D, Navarro ML, Holguin A. Drug resistance in children and adolescents with HIV in Panama.. The Journal of antimicrobial chemotherapy. 2022",15,YR,,,Y,,,20230323,,HP,ES,ES,EFAVIRENZ,HIV viraemia;Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,218984483,OT,,,,,,,,,218984483,1,Perinatal HIV infection
21903570,219035701,1,I,,20230116,20230124,20230124,EXP,,CA-MYLANLABS-2023M1006793,MYLAN,,54,YR,,M,Y,,,20230124,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,219035701,DS,,,,,,,,,219035701,1,Bipolar disorder
21903572,219035721,1,I,,20230116,20230124,20230124,EXP,,CA-MYLANLABS-2023M1006787,MYLAN,,,,,M,Y,,,20230124,,CN,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction,219035721,HO,,,,,,,,,219035721,1,Product used for unknown indication
21903581,219035811,1,I,,20230116,20230124,20230124,EXP,,CA-MYLANLABS-2023M1006801,MYLAN,,54,YR,,M,Y,,,20230124,,CN,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,219035811,OT,,,,,,,,,219035811,1,Bipolar disorder
21903582,219035821,1,I,,20230116,20230124,20230124,EXP,,CA-MYLANLABS-2023M1006803,MYLAN,,54,YR,,M,Y,,,20230124,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,219035821,HO,,,,,,,,,219035821,1,Bipolar disorder
21903583,219035831,1,I,,20230116,20230124,20230124,EXP,,CA-MYLANLABS-2023M1007301,MYLAN,,54,YR,,M,Y,,,20230124,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction,219035831,OT,,,,,,,,,219035831,1,Product used for unknown indication
21909664,219096641,1,I,,20230119,20230125,20230125,EXP,,MW-VIIV HEALTHCARE LIMITED-US2023GSK008325,VIIV,"Painschab MS, Mponda M, Tomoka T, Kampani C, Chimzimu F, Fedoriw Y et al.. Case report: Multicentric Castleman disease as a manifestation of immune reconstitution inflammatory syndrome in Malawi. Frontiers in Oncology. 2022;12",,,,,Y,,,20230125,,HP,MW,MW,EFAVIRENZ,Anaemia;Castleman's disease;Condition aggravated;Fatigue;Human herpesvirus 8 infection;Immune reconstitution inflammatory syndrome;Lymphadenitis viral;Lymphadenopathy;Malaise;Myalgia;Night sweats;Pyrexia;Virologic failure;Weight decreased,219096641,OT,,,,,,,,,219096641,1,HIV infection
21909665,219096651,1,I,,20230119,20230125,20230125,EXP,,MW-GSK-US2023GSK008325,GLAXOSMITHKLINE,"Painschab MS, Mponda M, Tomoka T, Kampani C, Chimzimu F, Fedoriw Y et al.. Case report: Multicentric Castleman disease as a manifestation of immune reconstitution inflammatory syndrome in Malawi. Frontiers in Oncology. 2022;12",,,,,Y,,,20230125,,HP,MW,MW,EFAVIRENZ,Anaemia;Castleman's disease;Condition aggravated;Fatigue;Human herpesvirus 8 infection;Immune reconstitution inflammatory syndrome;Lymphadenitis viral;Lymphadenopathy;Malaise;Myalgia;Night sweats;Pyrexia;Virologic failure;Weight decreased,219096651,OT,,,,,,,,,219096651,1,HIV infection
21909893,219098931,1,I,,20230119,20230125,20230125,EXP,,PH-MYLANLABS-2023M1009033,MYLAN,"Yanes RR, Malijan GMB, Escora-Garcia LK, Ricafrente SAM, Salazar MJ, Suzuki S, et al. Detection of SARS-CoV-2 and HHV-8 from a large pericardial effusion in an HIV-positive patient with COVID-19 and clinically diagnosed Kaposi sarcoma: a case report. Trop-Med-Health 2022;50:No. 1.",3,DEC,,M,Y,,,20230125,,HP,PH,PH,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Drug ineffective,219098931,DE,,,,,,,,,219098931,1,COVID-19
21911786,219117861,1,I,,20230123,20230125,20230125,EXP,,IN-GILEAD-2023-0614073,GILEAD,"Barman B, Jamil M, Dey B, Ish P. Tuberculosis and human immunodeficiency virus coinfection complicated by immune reconstitution inflammatory syndrome. Indian Journal of Sexually Transmitted Diseases and AIDS. 2022;43(2):229-230. doi:10.4103/ijstd.ijstd_99_21",28,YR,A,M,Y,,,20230125,,MD,IN,IN,EFAVIRENZ,Immune reconstitution inflammatory syndrome,219117861,OT,,,,,,,,,219117861,1,HIV infection
21915414,219154141,1,I,,20230116,20230126,20230126,EXP,,CA-MYLANLABS-2023M1008131,MYLAN,,54,YR,,M,Y,,,20230126,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,219154141,OT,,,,,,,,,219154141,1,Bipolar disorder
21917354,219173541,1,I,,20230118,20230126,20230126,EXP,,CA-009507513-2301CAN007212,MERCK,,,,,M,Y,,,20230126,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction,219173541,HO,,,,,,,,,219173541,1,Product used for unknown indication
21918755,219187551,1,I,,20230116,20230127,20230127,EXP,,US-CIPLA LTD.-2023US00317,CIPLA,"Church LWP, Judson MA, Chopra A. Paradoxical Reactions and the Immune Reconstitution In?ammatory Syndrome. Microbiol Spectrum. 2017;5 (2):1 to 15",39,YR,,F,Y,,,20230127,,HP,US,US,EFAVIRENZ,Disease recurrence;Sarcoidosis;Treatment noncompliance,219187551,HO,,,,,,,,,219187551,1,HIV infection
21919953,219199531,1,I,,20230123,20230127,20230127,EXP,,NL-MYLANLABS-2023M1008516,MYLAN,"Gordijn R, Wessels W, Kriek E, Nicolai P J M, Elzevier W H, Visser L etal. Patient reporting of sexual adverse events on an online platform for medication experiences. British Journal of Clinical Pharmacology. 2022;88(12):5326-5335",,,,M,Y,,,20230127,,HP,NL,NL,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Sexual dysfunction,219199531,OT,,,,,,,,,219199531,1,Product used for unknown indication
21920283,219202835,5,F,20100629,20230223,20230127,20230306,EXP,,GB-HORMOSAN PHARMA GMBH-2022-15144,LUPIN,,3,MON,,M,Y,,,20230306,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Caesarean section;Cleft lip and palate;Foetal exposure during pregnancy;Hepatic cytolysis;Hydrops foetalis;Intentional product use issue;Off label use;Trisomy 18;Ultrasound antenatal screen,219202835,HO,,,219202835,1,20171006,20180205,4,MON,219202835,1,HIV infection
21921876,219218762,2,F,,20230302,20230127,20230310,EXP,,CH-GILEAD-2023-0614278,GILEAD,,55,YR,A,M,Y,,,20230310,,HP,CH,CH,SUSTIVA,Drug resistance;Virologic failure,219218762,OT,,,,,,,,,219218762,1,Product used for unknown indication
21923583,219235831,1,I,,20230123,20230130,20230130,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2023-013331,BRISTOL MYERS SQUIBB,,54,YR,A,M,Y,,,20230130,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Death,219235831,OT,,,,,,,,,219235831,1,HIV infection
21923998,219239981,1,I,,20230125,20230130,20230130,PER,,US-AMGEN-USASP2023014474,AMGEN,,,,A,M,Y,,,20230130,,HP,US,US,EFAVIRENZ FARMOZ,Drug ineffective,,,,,,,,,,,219239981,1,Psoriatic arthropathy
21924495,219244951,1,I,,20221208,20230130,20230130,PER,,US-STRIDES ARCOLAB LIMITED-2022SP016616,STRIDES,,45,YR,,F,Y,,,20230130,,HP,US,US,EFAVIRENZ,Maternal exposure during pregnancy,,,,,219244951,1,,,12,WK,219244951,1,Product used for unknown indication
21924600,219246002,2,F,,20230206,20230130,20230220,EXP,,ZA-CIPLA (EU) LIMITED-2023ZA00314,CIPLA,"Botha JC, Steegen K, Edoo M, Nel J, Van Zyl GU.. Low-level viraemia despite emergence of dolutegravir-resistant variants. Southern African Journal of HIV Medicine. 2022;23 (1):1 to 4",,,,,Y,,,20230220,,MD,ZA,ZA,EFAVIRENZ,Diarrhoea;Drug resistance;Treatment noncompliance;Viral load increased;Virologic failure,219246002,HO,,,219246002,1,2012,2015,,,219246002,1,HIV infection
21925192,219251921,1,I,,20230119,20230130,20230130,EXP,,PH-STRIDES ARCOLAB LIMITED-2023SP001264,STRIDES,"Yanes RR, Malijan GMB, Escora-Garcia LK, Ricafrente SAM, Salazar MJ, Suzuki S, et al.. Detection of SARS-CoV-2 and HHV-8 from a large pericardial effusion in an HIV-positive patient with COVID-19 and clinically diagnosed Kaposi sarcoma: a case report.. Trop-Med-Health. 2022;50(1)",3,DEC,,M,Y,,,20230130,,HP,PH,PH,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Acute respiratory failure;Drug ineffective;Enterobacter infection;Pneumonia;Septic shock,219251921,DE,,,,,,,,,219251921,1,Supportive care
21930071,219300711,1,I,,20230119,20230131,20230131,EXP,,PH-STERISCIENCE B.V.-2023-ST-000359,Steriscience PTE,"Yanes RR, Malijan GMB, Escora-Garcia LK, Ricafrente SAM, Salazar MJ, Suzuki S, et al.. Detection of SARS-CoV-2 and HHV-8 from a large pericardial effusion in an HIV-positive patient with COVID-19 and clinically diagnosed Kaposi sarcoma: a case report. Trop-Med-Health. 2022;50 No:1",3,DEC,,M,Y,,,20230131,,HP,PH,PH,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Drug ineffective,219300711,DE,,,,,,,,,219300711,1,Pneumonia
21934380,219343801,1,I,,20230123,20230201,20230201,EXP,,ZW-AUROBINDO-AUR-APL-2023-004075,AUROBINDO,"Mutambanengwe-Jacob MT, Maponga CC, Amico KR, Ngara B, Yende-Zuma N, Chawana TD, et al. Impact of Motivational Enhanced Adherence Counseling and Point-of-Care Viral Load Monitoring on Viral Load Outcome in Women on Life-Long ART: A Randomized Pilot Study. AIDS Research and Treatment. 2022;13",,,,F,Y,,,20230201,,HP,ZW,ZW,"EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE",Virologic failure,219343801,OT,,,,,,,,,219343801,1,HIV infection
21934926,219349261,1,I,,20230123,20230201,20230201,EXP,,ZW-AUROBINDO-AUR-APL-2023-004076,AUROBINDO,"Mutambanengwe-Jacob MT, Maponga CC, Amico KR, Ngara B, Yende-Zuma N, Chawana TD, et al.. Impact of Motivational Enhanced Adherence Counseling and Point-of-Care Viral Load Monitoring on Viral Load Outcome in Women on Life-Long ART: A Randomized Pilot Study. AIDS Research and Treatment. 2022;13",,,,F,Y,,,20230201,,HP,ZW,ZW,"EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE",Virologic failure,219349261,OT,,,,,,,,,219349261,1,HIV infection
21935581,219355811,1,I,,20230125,20230201,20230201,EXP,,FR-MYLANLABS-2023M1010955,MYLAN,"Faure C, Chassery M, Ores R, Audo I. Didanosine-induced Retinopathy: New Insights with Long-term Follow-up. Ocular-Immunol-Inflamm 2022;30(7):1625-1632.",56,YR,,M,Y,,,20230201,,MD,FR,FR,EFAVIRENZ,Labelled drug-disease interaction medication error;Retinopathy,219355811,OT,,,,,,,,,219355811,1,HIV infection
21937868,219378681,1,I,,20230116,20230201,20230201,EXP,,CA-MYLANLABS-2023M1006243,MYLAN,,,,,M,Y,,,20230201,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,219378681,HO,,,,,,,,,219378681,1,Product used for unknown indication
21944224,219442241,1,I,,20230123,20230202,20230202,EXP,,CA-TEVA-2023-CA-2850572,TEVA,,54,YR,A,M,Y,,,20230202,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,219442241,OT,,,,,,,,,219442241,1,HIV infection
21944225,219442251,1,I,,20230123,20230202,20230202,EXP,,CA-TEVA-2023-CA-2850534,TEVA,,,,,M,Y,,,20230202,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,219442251,HO,,,,,,,,,219442251,1,Product used for unknown indication
21944229,219442291,1,I,,20230123,20230202,20230202,EXP,,CA-TEVA-2023-CA-2850580,TEVA,,54,YR,A,M,Y,,,20230202,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,219442291,OT,,,,,,,,,219442291,1,HIV infection
21948224,219482241,1,I,,20230123,20230203,20230203,EXP,,CA-TEVA-2023-CA-2850542,TEVA,,54,YR,A,M,Y,,,20230202,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,219482241,HO,,,,,,,,,219482241,1,HIV infection
21948225,219482251,1,I,,20230123,20230203,20230203,EXP,,CA-TEVA-2023-CA-2850544,TEVA,,,,,M,Y,,,20230202,,CN,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction,219482251,HO,,,,,,,,,219482251,1,Product used for unknown indication
21948227,219482271,1,I,,20230123,20230203,20230203,EXP,,CA-TEVA-2023-CA-2850536,TEVA,,54,YR,A,M,Y,,,20230202,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,219482271,OT,,,,,,,,,219482271,1,HIV infection
21948229,219482291,1,I,,20230123,20230203,20230203,EXP,,CA-TEVA-2023-CA-2850541,TEVA,,54,YR,A,M,Y,,,20230202,,CN,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,219482291,OT,,,,,,,,,219482291,1,HIV infection
21949113,219491132,2,F,20120521,20230213,20230203,20230215,EXP,,NVSC2019GB122185,NOVARTIS,,43,YR,,F,Y,,,20230215,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Drug abuse;Exposure during pregnancy;Hepatic cytolysis;Hydrops foetalis;Intentional product use issue;Maternal exposure during pregnancy;Off label use;Ultrasound antenatal screen,219491132,OT,,,219491132,3,20180205,20180205,1,DAY,219491132,1,HIV infection
21952152,219521521,1,I,,20230202,20230203,20230203,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-2023-016252,BRISTOL MYERS SQUIBB,,27,YR,A,M,Y,,,20230203,,HP,GB,GB,EFAVIRENZ,Neurotoxicity,219521521,OT,,,,,,,,,219521521,1,Product used for unknown indication
21952729,219527291,1,I,,20230125,20230204,20230204,EXP,,IN-HETERO-HET2023IN00198,HETERO,"Barman B, Jamil Md, Dey B, Ish P. Tuberculosis and human immunodeficiency virus coinfection complicated by immune reconstitution inflammatory syndrome. Indian Journal of Sexually Transmitted Diseases and AIDS. 2022;43(2):229-230",28,YR,,M,Y,,,20230204,,MD,IN,IN,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Paradoxical drug reaction,219527291,OT,,,,,,,,,219527291,1,Antiretroviral therapy
21953103,219531031,1,I,,20230129,20230204,20230204,EXP,,IN-HETERO-HET2023IN00206,HETERO,"Simon M, Meah A. Tenofovir as a cause of acquired fanconi^s syndrome. Annals of African Medicine. 2023;22:128-130",53,YR,,F,Y,,,20230204,,HP,IN,IN,EFAVIRENZ;LAMIVUDINE,Fanconi syndrome;Metabolic encephalopathy,219531031,HO,,,,,,,,,219531031,1,HIV infection
21953157,219531572,2,F,20180112,20230131,20230204,20230209,EXP,,NVSC2023GB021209,NOVARTIS,,,,,,Y,,,20230209,,HP,GB,GB,EFAVIRENZ,Cleft lip and palate;Trisomy 18,219531572,HO,,,,,,,,,219531572,1,Foetal exposure during pregnancy
21958982,219589822,2,F,,20230125,20230206,20230209,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-2023-010569,BRISTOL MYERS SQUIBB,"Barman B, Jamil M, Dey B, Ish P. Tuberculosis and human immunodeficiency virus coinfection complicated by immune reconstitution inflammatory syndrome. Indian Journal of Sexually Transmitted Diseases and AIDS. 2022 Nov 17;43(2):229-30.doi:10.4103/ijstd.ijstd_99_21.",28,YR,A,M,Y,,,20230210,,MD,IN,IN,EFAVIRENZ,Immune reconstitution inflammatory syndrome,219589822,OT,,,,,,,,,219589822,1,Antiretroviral therapy
21959365,219593651,1,I,,20230202,20230206,20230206,EXP,,GB-MYLANLABS-2023M1012705,MYLAN,,27,YR,,M,Y,,,20230206,,HP,GB,GB,EFAVIRENZ,Neurotoxicity,219593651,OT,,,,,,,,,219593651,1,Product used for unknown indication
21960652,219606521,1,I,,20230123,20230207,20230207,EXP,,MW-CIPLA (EU) LIMITED-2023MW00432,CIPLA,"Painschab MS, Mponda M, Tomoka T, Kampani C, Chimzimu F, Fedoriw Y et.al. Multicentric Castleman disease as a manifestation of immune reconstitution inflammatory syndrome in Malawi. Frontiers in oncology. 2022;12:969135:01 to 06",,,,,Y,,,20230207,,HP,MW,MW,EFAVIRENZ,Castleman's disease;Haemoglobin decreased;Immune reconstitution inflammatory syndrome;Platelet count decreased;Virologic failure,219606521,OT,,,,,,,,,219606521,1,HIV infection
21962089,219620891,1,I,20201228,20230130,20230207,20230207,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK014191,VIIV,"Cui X, Su F, Ye H, Jiang Y, Guo X. Disseminated talaromycosis complicated by recurrent gastrointestinal bleeding and hemorrhagic shock: a case report. BMC Infectious Diseases. 2022;22 (1)",,,,,Y,,,20230207,,HP,CN,CN,EFAVIRENZ,Abdominal lymphadenopathy;Abdominal pain;Diarrhoea;Discomfort;Drug interaction;Faeces discoloured;Gastrointestinal haemorrhage;Gastrointestinal inflammation;Hypotension;Liver function test abnormal;Myelosuppression;Pathogen resistance;Penicillium infection;Rash papular;Shock haemorrhagic;Skin lesion;Skin necrosis;Ulcer;Virologic failure,219620891,OT,,,219620891,1,,,5,YR,219620891,1,HIV infection
21962092,219620921,1,I,20201228,20230130,20230207,20230207,EXP,,CN-GSK-CN2023GSK014191,GLAXOSMITHKLINE,"Cui X, Su F, Ye H, Jiang Y, Guo X. Disseminated talaromycosis complicated by recurrent gastrointestinal bleeding and hemorrhagic shock: a case report. BMC Infectious Diseases. 2022;22 (1)",,,,,Y,,,20230207,,HP,CN,CN,EFAVIRENZ,Abdominal lymphadenopathy;Abdominal pain;Diarrhoea;Discomfort;Drug interaction;Faeces discoloured;Gastrointestinal haemorrhage;Gastrointestinal inflammation;Hypotension;Liver function test abnormal;Myelosuppression;Pathogen resistance;Penicillium infection;Rash papular;Shock haemorrhagic;Skin lesion;Skin necrosis;Ulcer;Virologic failure,219620921,OT,,,219620921,1,,,5,YR,219620921,1,HIV infection
21962826,219628261,1,I,,20230201,20230207,20230207,EXP,,ES-MYLANLABS-2023M1012000,MYLAN,"Gil H, Delgado E, Benito S, Moreno-Lorenzo M, Thomson MM. Factors associated with HIV-1 resistance to integrase strand transfer inhibitors in Spain: Implications for dolutegravir-containing regimens. Frontiers in Microbiology.. 2022;13",18,YR,,F,Y,,,20230207,,HP,ES,ES,EFAVIRENZ,Pathogen resistance;Treatment noncompliance;Viral mutation identified,219628261,OT,,,,,,,,,219628261,1,HIV infection
21964425,219644251,1,I,20220110,20230201,20230207,20230207,EXP,,FR-MYLANLABS-2023M1011801,MYLAN,,41,YR,,F,Y,,,20230207,,MD,FR,FR,EFAVIRENZ,Pathogen resistance;Treatment noncompliance;Viral mutation identified,219644251,OT,,,219644251,1,20220101,,,,219644251,1,HIV infection
21964445,219644451,1,I,,20230201,20230207,20230207,EXP,,ES-MYLANLABS-2023M1012004,MYLAN,"Gil H, Delgado E, Benito S, Moreno-Lorenzo M, Thomson MM.. Factors associated with HIV-1 resistance to integrase strand transfer inhibitors in Spain: Implications for dolutegravir-containing regimens.. Frontiers in Microbiology.. 2022;13",31,YR,,M,Y,,,20230207,,HP,ES,ES,EFAVIRENZ,Pathogen resistance;Treatment noncompliance;Viral mutation identified,219644451,OT,,,,,,,,,219644451,1,HIV infection
21964698,219646981,1,I,,20230206,20230207,20230207,EXP,,CA-BAUSCH-BL-2023-002290,BAUSCH AND LOMB,,54,YR,,M,Y,,,20230207,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,219646981,OT,,,,,,,,,219646981,1,Bipolar disorder
21965274,219652741,1,I,,20230125,20230208,20230208,EXP,,IN-MACLEODS PHARMACEUTICALS US LTD-MAC2023039666,MACLEODS,"Barman B, Jamil Md, Dey B, Ish P.. Tuberculosis and human immunodeficiency virus coinfection complicated by immune reconstitution inflammatory syndrome. Indian Journal of Sexually Transmitted Diseases and AIDS. 2022;43(2):229-30",,,,,Y,,,20230208,,MD,IN,IN,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Paradoxical drug reaction,219652741,OT,,,,,,,,,219652741,1,Antiretroviral therapy
21967152,219671521,1,I,,20230131,20230208,20230208,EXP,,CA-MYLANLABS-2023M1013277,MYLAN,,54,YR,,M,Y,,,20230208,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,219671521,OT,,,,,,,,,219671521,1,Product used for unknown indication
21970432,219704321,1,I,,20230125,20230209,20230209,EXP,,IN-CIPLA (EU) LIMITED-2023IN00390,CIPLA,"Barman B, Jamil M, Dey B, Ish P. Tuberculosis and human immunodeficiency virus coinfection complicated by immune reconstitution inflammatory syndrome. Indian Journal of Sexually Transmitted Diseases and AIDS. 2022;43(2):229 to 230",,,,,Y,,,20230209,,MD,IN,IN,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Paradoxical drug reaction,219704321,OT,,,,,,,,,219704321,1,HIV infection
21974781,219747811,1,I,,20230206,20230209,20230209,EXP,,CA-BAUSCH-BL-2023-002291,BAUSCH AND LOMB,,54,YR,,M,Y,,,20230209,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,219747811,OT,,,,,,,,,219747811,1,Bipolar disorder
21974782,219747821,1,I,,20230206,20230209,20230209,EXP,,CA-BAUSCH-BL-2023-002294,BAUSCH AND LOMB,,,,,M,Y,,,20230209,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction,219747821,HO,,,,,,,,,219747821,1,Product used for unknown indication
21980676,219806761,1,I,,20230202,20230211,20230211,EXP,,GB-AUROBINDO-AUR-APL-2023-005642,AUROBINDO,,27,YR,,M,Y,,,20230211,,HP,GB,GB,EFAVIRENZ,Neurotoxicity,219806761,OT,,,,,,,,,219806761,1,Product used for unknown indication
21981649,219816491,1,I,,20230203,20230212,20230212,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-2022-094992,BRISTOL MYERS SQUIBB,"Calcagno A, Celani L, Trunfio M, Orofino G, Imperiale D, Atzori C, et al. Alzheimer dementia in people living with HIV. Neurology: Clinical Practice. 2021; 11(5): e627-33. 10.1212/CPJ.0000000000001060",71,YR,E,M,Y,,,20230212,,MD,IT,IT,EFAVIRENZ,Dementia Alzheimer's type,219816491,OT,,,,,,,,,219816491,1,HIV infection
21983286,219832861,1,I,,20230206,20230213,20230213,EXP,,CA-BAUSCH-BL-2023-002309,BAUSCH AND LOMB,,54,YR,,M,Y,,,20230213,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction;Incorrect route of product administration;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose;Product use in unapproved indication,219832861,OT,,,,,,,,,219832861,1,Bipolar disorder
21984954,219849542,2,F,20211101,20230316,20230213,20230323,EXP,,US-VIIV HEALTHCARE LIMITED-US2023AMR018948,VIIV,,,,,,Y,,,20230323,,CN,US,US,SUSTIVA,Hypokinesia;Intentional product misuse;Paralysis;Thrombocytopenia,219849542,DS,,,219849542,1,2019,2019,,,219849542,1,HIV infection
21987515,219875151,1,I,20201201,20230131,20230214,20230214,EXP,,CN-CIPLA LTD.-2023CN00833,CIPLA,"Cui X, Su F, Ye H, Jiang Y, Guo X.. Disseminated talaromycosis complicated by recurrent gastrointestinal bleeding and hemorrhagic shock: a case report. BMC Infectious Diseases. 2022;22:238:1 to 6",,,,,Y,,,20230214,,HP,CN,CN,EFAVIRENZ,Discomfort;Virologic failure,219875151,OT,,,219875151,1,2015,202011,4,DAY,219875151,1,HIV infection
21988564,219885641,1,I,,20230205,20230214,20230214,EXP,,ZA-JNJFOC-20230215068,JOHNSON AND JOHNSON,,,,A,,Y,,,20230214,,HP,ZA,ZA,EFAVIRENZ,Alanine aminotransferase increased;Anaemia;Arthralgia;Drug ineffective;Drug interaction;Mental disorder;Musculoskeletal toxicity;Neutropenia;Thrombocytopenia,219885641,LT,,,,,,,,,219885641,1,Tuberculosis
21990501,219905011,1,I,,20230208,20230214,20230214,EXP,,ZA-MYLANLABS-2023M1015516,MYLAN,"Botha JC, Steegen K, Edoo M, Nel J, van Zyl GU. Low-level viraemia despite emergence of dolutegravir-resistant variants. South-Afr-J-HIV-Med 2022;23(1):a1398.",,,A,M,Y,,,20230214,,HP,ZA,ZA,EFAVIRENZ,Diarrhoea;Pathogen resistance;Virologic failure,219905011,OT,,,,,,,,,219905011,1,HIV infection
21994984,219949841,1,I,,20230213,20230215,20230215,EXP,CA-HEALTH-05970570,CA-GILEAD-2023-0616696,GILEAD,,54,YR,A,M,Y,,,20230215,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,219949841,OT,,,,,,,,,219949841,1,Product used for unknown indication
21996663,219966631,1,I,,20230208,20230215,20230215,EXP,,IN-MYLANLABS-2023M1016669,MYLAN,"Parvez S, Goel P, Sarna MK, Rijhwani P. HIV-Associated Cutaneous Kaposi^s Sarcoma induced by IRIS following Antiretroviral Therapy. J-Indian-Acad-Clin-Med 2022;23(3):154-156.",30,YR,,M,Y,,,20230215,,HP,IN,IN,EFAVIRENZ,Immune reconstitution inflammatory syndrome associated Kaposi's sarcoma;Paradoxical drug reaction,219966631,OT,,,,,,,,,219966631,1,HIV infection
21997590,219975901,1,I,,20230201,20230216,20230216,EXP,,IN-MACLEODS PHARMA EU LTD-MAC2023039759,MACLEODS,"Simon M, Meah A.. Tenofovir as a cause of acquired fanconi^s syndrome. Annals of African Medicine. 2023;22(1):128",,,,,Y,,,20230213,,HP,IN,IN,Lamivudine/ efavirenz,Addison's disease;Fanconi syndrome,219975901,HO,,,,,,,,,219975901,1,HIV infection
21998557,219985571,1,I,,20230208,20230216,20230216,EXP,,IN-STRIDES ARCOLAB LIMITED-2023SP002348,STRIDES,"Parvez S, Goel P, Sarna MK, Rijhwani P.. HIV-Associated Cutaneous Kaposi^s Sarcoma induced by IRIS following Antiretroviral Therapy.. J-Indian-Acad-Clin-Med.. 2022;23(3):154-156.",30,YR,,M,Y,,,20230216,,HP,IN,IN,EFAVIRENZ,Immune reconstitution inflammatory syndrome associated Kaposi's sarcoma;Paradoxical drug reaction,219985571,OT,,,,,,,,,219985571,1,HIV infection
21999608,219996081,1,I,,20230206,20230216,20230216,EXP,,FR-TEVA-2023-FR-2855921,TEVA,,56,YR,A,M,Y,,,20230216,,MD,FR,FR,EFAVIRENZ,Drug interaction;Retinopathy,219996081,OT,,,,,,,,,219996081,1,HIV infection
22003331,220033311,1,I,,20230202,20230217,20230217,EXP,,GB-MACLEODS PHARMA EU LTD-MAC2023039770,MACLEODS,,,,,,Y,,,20230215,,HP,GB,GB,EFAVIRENZ,Neurotoxicity,220033311,OT,,,,,,,,,220033311,1,Product used for unknown indication
22005246,220052461,1,I,,20230210,20230217,20230217,EXP,,ES-GSK-ES2023GSK022581,GLAXOSMITHKLINE,"Hernanz-Lobo A, Ruiz Saez B, Carrasco Garcia I, Mino-Leon G, Juarez J, Pavia Ruz N et al. New diagnosis of mother-to-child transmission of HIV in 8 Latin-American countries during 2018. BMC Infectious Diseases. 2022;22(1)",,,,,Y,,,20230217,,HP,ES,ES,EFAVIRENZ,Condition aggravated;Foetal exposure during pregnancy;HIV infection;Human immunodeficiency virus transmission;Virologic failure,220052461,OT,,,,,,,,,220052461,1,HIV infection
22005247,220052471,1,I,,20230210,20230217,20230217,EXP,,ES-VIIV HEALTHCARE LIMITED-ES2023GSK022581,VIIV,"Hernanz-Lobo A, Ruiz Saez B, Carrasco Garcia I, Mino-Leon G, Juarez J, Pavia Ruz N et al. New diagnosis of mother-to-child transmission of HIV in 8 Latin-American countries during 2018. BMC Infectious Diseases. 2022;22(1)",,,,,Y,,,20230217,,HP,ES,ES,EFAVIRENZ,Condition aggravated;Foetal exposure during pregnancy;HIV infection;Human immunodeficiency virus transmission;Virologic failure,220052471,OT,,,,,,,,,220052471,1,HIV infection
22006388,220063883,3,F,,20230217,20230217,20230302,EXP,,CN-GILEAD-2023-0616851,GILEAD,"Hengli L, Xia L, Xinping Y, Cuixian Y, Mi Z, Huiqin L, et al.. Analysis on clinical characteristics of tenofovir disoproxil fumarate-related Fanconi syndrome in patients with HIV infection/AIDS. ADRJ. 2023;25(1):Unk. doi:10.3760/cma.j.cn114015?20220603?00491",19,YR,A,F,Y,38,KG,20230302,,MD,CN,CN,EFAVIRENZ,Fanconi syndrome acquired,220063883,HO,,,,,,,,,220063883,1,HIV infection
22010238,220102381,1,I,,20230213,20230220,20230220,EXP,CA-HEALTH-05970570,CA-VIIV HEALTHCARE LIMITED-CA2023025043,VIIV,,,,,,Y,,,20230220,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,220102381,HO,,,,,,,,,220102381,1,Product used for unknown indication
22010271,220102711,1,I,,20230213,20230220,20230220,EXP,CA-HEALTH-05970570,CA-GSK-CA2023025043,GLAXOSMITHKLINE,,,,,,Y,,,20230220,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,220102711,OT,,,,,,,,,220102711,1,Product used for unknown indication
22010455,220104552,2,F,,20230214,20230220,20230222,EXP,,NVSC2023CA035449,NOVARTIS,,54,YR,,M,Y,,,20230222,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Hyperhidrosis;Major depression;Musculoskeletal stiffness;Neuroleptic malignant syndrome;Pyrexia,220104552,HO,,,220104552,1,,,10,DAY,220104552,1,Bipolar disorder
22011038,220110383,3,F,,20230217,20230220,20230309,EXP,,CN-GSK-CN2023026500,GLAXOSMITHKLINE,,,,,,Y,,,20230309,,MD,CN,CN,EFAVIRENZ,Fanconi syndrome acquired,220110383,HO,,,,,,,,,220110383,1,HIV infection
22011039,220110393,3,F,,20230217,20230220,20230309,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023026500,VIIV,,,,,,Y,,,20230309,,MD,CN,CN,EFAVIRENZ,Fanconi syndrome acquired,220110393,HO,,,,,,,,,220110393,1,HIV infection
22014511,220145111,1,I,,20230208,20230221,20230221,EXP,,CN-CIPLA LTD.-2023CN00980,CIPLA,"Wang Z, Zhang M, Wang J, Liu L, Chen J, Zhang R et al.. Efficacy of Efavirenz-Based Regimen in Antiretroviral-Naive Patients with HIV-1 V179D/E Mutations in Shanghai, China. Infect Dis Ther. 2023;12:245 to 255",,,,,Y,,,20230221,,HP,CN,CN,EFAVIRENZ,Drug resistance;Virologic failure,220145111,OT,,,,,,,,,220145111,1,HIV infection
22014512,220145121,1,I,,20230208,20230221,20230221,EXP,,CN-CIPLA LTD.-2023CN00982,CIPLA,"Wang Z, Zhang M, Wang J, Liu L, Chen J, Zhang R et.al. Efficacy of Efavirenz-Based Regimen in Antiretroviral- Na??ve Patients with HIV-1 V179D/E Mutations in Shanghai, China. Infect Dis Ther. 2023;12:245 to 255",,,,,Y,,,20230221,,HP,CN,CN,EFAVIRENZ,Drug resistance;Virologic failure,220145121,OT,,,,,,,,,220145121,1,HIV infection
22014515,220145151,1,I,,20230208,20230221,20230221,EXP,,CN-CIPLA LTD.-2023CN00983,CIPLA,"Wang Z, Zhang M, Wang J, Liu L, Chen J, Zhang R et.al. Efficacy of Efavirenz-Based Regimen in Antiretroviral- Na??ve Patients with HIV-1 V179D/E Mutations in Shanghai, China. Infect Dis Ther. 2023;12:245 to 255",,,,,Y,,,20230221,,HP,CN,CN,EFAVIRENZ,Drug resistance;Virologic failure,220145151,OT,,,,,,,,,220145151,1,HIV infection
22014516,220145161,1,I,,20230208,20230221,20230221,EXP,,CN-CIPLA LTD.-2023CN00981,CIPLA,"Wang Z, Zhang M, Wang J, Liu L, Chen J, Zhang R et.al. Efficacy of Efavirenz-Based Regimen in Antiretroviral Naive Patients with HIV-1 V179D/E Mutations in Shanghai, China. Infect Dis Ther. 2023;12:245 to 255",,,,,Y,,,20230221,,HP,CN,CN,EFAVIRENZ,Drug resistance;Virologic failure,220145161,OT,,,,,,,,,220145161,1,HIV infection
22014517,220145171,1,I,,20230208,20230221,20230221,EXP,,CN-CIPLA LTD.-2023CN00986,CIPLA,"Wang Z, Zhang M, Wang J, Liu L, Chen J, Zhang R et.al. Efficacy of Efavirenz-Based Regimen in Antiretroviral Naive Patients with HIV-1 V179D/E Mutations in Shanghai, China. Infect Dis Ther. 2023;12:245 to 255",,,,,Y,,,20230221,,HP,CN,CN,EFAVIRENZ,Drug resistance;Virologic failure,220145171,OT,,,,,,,,,220145171,1,HIV infection
22015137,220151371,1,I,,20230208,20230221,20230221,EXP,,CN-CIPLA LTD.-2023CN00985,CIPLA,"Wang Z, Zhang M, Wang J, Liu L, Chen J, Zhang R et al.. Efficacy of Efavirenz-Based Regimen in Antiretroviral- Na??ve Patients with HIV-1 V179D/E Mutations in Shanghai, China. Infect Dis Ther. 2023;12:245-55",,,,,Y,,,20230221,,HP,CN,CN,EFAVIRENZ,Drug resistance;Virologic failure,220151371,OT,,,,,,,,,220151371,1,HIV infection
22015139,220151391,1,I,,20230208,20230221,20230221,EXP,,CN-CIPLA LTD.-2023CN00979,CIPLA,"Wang Z, Zhang M, Wang J, Liu L, Chen J, Zhang R et al.. Efficacy of Efavirenz-Based Regimen in Antiretroviral- Na??ve Patients with HIV-1 V179D/E Mutations in Shanghai, China. Infect Dis Ther. 2023;12:245 to 255",,,,,Y,,,20230221,,HP,CN,CN,EFAVIRENZ,Drug resistance;Virologic failure,220151391,OT,,,,,,,,,220151391,1,HIV infection
22015141,220151411,1,I,,20230208,20230221,20230221,EXP,,CN-CIPLA LTD.-2023CN00984,CIPLA,"Wang Z, Zhang M, Wang J, Liu L, Chen J, Zhang R et.al. Efficacy of Efavirenz-Based Regimen in Antiretroviral- Na??ve Patients with HIV-1 V179D/E Mutations in Shanghai, China. Infect Dis Ther. 2023;12:245 to 255",,,,,Y,,,20230221,,HP,CN,CN,EFAVIRENZ,Drug resistance;Virologic failure,220151411,OT,,,,,,,,,220151411,1,HIV infection
22016349,220163492,2,F,,20230316,20230221,20230323,EXP,,NVSC2023CA035210,NOVARTIS,,,,,M,Y,,,20230323,,CN,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction,220163492,OT,,,,,,,,,220163492,1,Product used for unknown indication
22017801,220178012,2,F,,20230213,20230221,20230327,EXP,,AU-GILEAD-2023-0617264,GILEAD,,,,A,F,Y,,,20230327,,CN,AU,AU,EFAVIRENZ,Feeling abnormal;Lipodystrophy acquired;Nightmare;Sleep disorder;Weight increased,220178012,OT,,,220178012,1,200808,201908,,,220178012,1,HIV infection
22019747,220197471,1,I,,20230214,20230222,20230222,EXP,,NVSC2023CA038407,NOVARTIS,,54,YR,,F,Y,,,20230222,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,220197471,HO,,,,,,,,,220197471,1,Depression
22020669,220206691,1,I,,20230214,20230222,20230222,EXP,,MW-MYLANLABS-2023M1018835,MYLAN,"Painschab MS, Mponda M, Tomoka T, Kampani C, Chimzimu F, Fedoriw Y, et al. Case report: Multicentric Castleman disease as a manifestation of immune reconstitution inflammatory syndrome in Malawi. Front-Oncol 2022;12:969135.",36,YR,,F,Y,,,20230222,,HP,MW,MW,EFAVIRENZ,Castleman's disease;Human herpesvirus 8 infection;Immune reconstitution inflammatory syndrome;Kaposi's sarcoma;Treatment failure;Unmasking of previously unidentified disease,220206691,OT,,,,,,,,,220206691,1,HIV infection
22021503,220215033,3,F,,20230217,20230222,20230309,EXP,,CN-GSK-CN2023029276,GLAXOSMITHKLINE,,,,,,Y,,,20230309,,MD,CN,CN,EFAVIRENZ,Fanconi syndrome acquired,220215033,OT,,,,,,,,,220215033,1,HIV infection
22021504,220215043,3,F,,20230217,20230222,20230309,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023029276,VIIV,,,,,,Y,,,20230309,,MD,CN,CN,EFAVIRENZ,Fanconi syndrome acquired,220215043,OT,,,,,,,,,220215043,1,HIV infection
22022015,220220152,2,F,,20230309,20230222,20230317,EXP,,NVSC2023CA037206,NOVARTIS,,54,YR,,M,Y,,,20230317,,CN,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Product use in unapproved indication;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,220220152,HO,,,,,,,,,220220152,1,Depression
22022496,220224961,1,I,,20230213,20230222,20230222,EXP,,US-GSK-US2023GSK027765,GLAXOSMITHKLINE,"Horner M, Hazra R, Barnholtz-Sloan JS, Shiels MS, Engels EA. Cancer risk among HIV-exposed uninfected children in the United States. AIDS. 2023;37 (3):549-551",,,,,Y,,,20230222,,HP,US,US,EFAVIRENZ,Ependymoma;Foetal exposure during pregnancy,220224961,OT,,,,,,,,,220224961,1,Prophylaxis against HIV infection
22022503,220225032,2,F,,20230309,20230222,20230317,EXP,,NVSC2023CA035182,NOVARTIS,,44,YR,,M,Y,,,20230317,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,220225032,HO,,,,,,,,,220225032,1,Depression
22023930,220239301,1,I,,20230215,20230223,20230223,EXP,,CA-APOTEX-2023AP003777,APOTEX,,54,YR,,M,Y,,,20230223,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,220239301,OT,,,,,,,,,220239301,1,HIV infection
22025735,220257351,1,I,,20230215,20230223,20230223,EXP,,CA-APOTEX-2023AP003746,APOTEX,,,,,M,Y,,,20230223,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction,220257351,HO,,,,,,,,,220257351,1,Product used for unknown indication
22026640,220266401,1,I,,20230223,20230223,20230223,EXP,,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-220660",BOEHRINGER INGELHEIM,"Hernanz-Lobo A, Ruiz Saez B, Carrasco Garcia I, Mino-Leon G, Juarez J, Pavia Ruz N et al. New diagnosis of mother-to-child transmission of HIV in 8 Latin-American countries during 2018. BMC Infectious Diseases. 2022;22(1):doi:10.1186/s12879-022-07311-8",4,YR,C,,Y,,,20230223,,HP,ES,ES,EFAVIRENZ,Condition aggravated;Foetal exposure during pregnancy;HIV infection;Human immunodeficiency virus transmission;Virologic failure,220266401,OT,,,,,,,,,220266401,1,HIV infection
22027059,220270591,1,I,,20230215,20230223,20230223,EXP,,CA-APOTEX-2023AP003784,APOTEX,,54,YR,,M,Y,,,20230223,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction;Incorrect route of product administration;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose;Product use in unapproved indication,220270591,DE,,,,,,,,,220270591,1,HIV infection
22027340,220273401,1,I,,20230215,20230223,20230223,EXP,,CA-APOTEX-2023AP003787,APOTEX,,54,YR,,M,Y,,,20230223,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,220273401,OT,,,,,,,,,220273401,1,HIV infection
22027879,220278791,1,I,,20230213,20230223,20230223,EXP,,US-VIIV HEALTHCARE LIMITED-US2023GSK027765,VIIV,"Horner M, Hazra R, Barnholtz-Sloan JS, Shiels MS, Engels EA. Cancer risk among HIV-exposed uninfected children in the United States. AIDS. 2023;37 (3):549-551",,,,,Y,,,20230223,,HP,US,US,EFAVIRENZ,Ependymoma;Foetal exposure during pregnancy,220278791,OT,,,,,,,,,220278791,1,Prophylaxis against HIV infection
22029095,220290952,2,F,,20230217,20230223,20230303,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023029360,VIIV,,,,,,Y,,,20230303,,MD,CN,CN,EFAVIRENZ,Fanconi syndrome acquired,220290952,OT,,,,,,,,,220290952,1,HIV infection
22029096,220290962,2,F,,20230217,20230223,20230303,EXP,,CN-GSK-CN2023029360,GLAXOSMITHKLINE,,,,,,Y,,,20230303,,MD,CN,CN,EFAVIRENZ,Fanconi syndrome acquired,220290962,OT,,,,,,,,,220290962,1,HIV infection
22029391,220293911,1,I,,20230215,20230223,20230223,EXP,,NVSC2023CA037088,NOVARTIS,,44,YR,,M,Y,,,20230223,,HP,CA,CA,SUSTIVA,Drug interaction;Psychiatric decompensation,220293911,HO,,,,,,,,,220293911,1,Depression
22032938,220329381,1,I,,20230214,20230224,20230224,EXP,,MW-STRIDES ARCOLAB LIMITED-2023SP002539,STRIDES,"Painschab MS, Mponda M, Tomoka T, Kampani C, Chimzimu F, Fedoriw Y, et al.. Case report: Multicentric Castleman disease as a manifestation of immune reconstitution inflammatory syndrome in Malawi.. Front-Oncol. 2022;12969135.",36,YR,,F,Y,,,20230224,,HP,MW,MW,EFAVIRENZ,Castleman's disease;Herpes virus infection;Immune reconstitution inflammatory syndrome;Kaposi's sarcoma;Treatment failure;Unmasking of previously unidentified disease,220329381,OT,,,,,,,,,220329381,1,HIV infection
22034775,220347752,2,F,,20230214,20230224,20230303,EXP,,CN-GSK-CN2023030319,GLAXOSMITHKLINE,"Hengli L, Xia L, Xinping Y, Cuixian Y, Mi Z ,Huiqin L. etal. Analysis on clinical characteristics of tenofovir disoproxil fumarate-related Fanconi syndrome in patients with HIV infection/AIDS. ADRJ. 2023;25(1):unk",,,,,Y,,,20230303,,MD,CN,CN,EFAVIRENZ,Fanconi syndrome acquired,220347752,HO,,,,,,,,,220347752,1,HIV infection
22034776,220347762,2,F,,20230214,20230224,20230303,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023030319,VIIV,"Hengli L, Xia L, Xinping Y, Cuixian Y, Mi Z ,Huiqin L. etal. Analysis on clinical characteristics of tenofovir disoproxil fumarate-related Fanconi syndrome in patients with HIV infection/AIDS. ADRJ. 2023;25(1):unk",,,,,Y,,,20230303,,MD,CN,CN,EFAVIRENZ,Fanconi syndrome acquired,220347762,HO,,,,,,,,,220347762,1,HIV infection
22037727,220377271,1,I,,20230215,20230227,20230227,EXP,,CA-APOTEX-2023AP003799,APOTEX,,54,YR,,M,Y,,,20230227,,CN,CA,CA,EFAVIRENZ,Drug interaction;Psychiatric decompensation,220377271,OT,,,,,,,,,220377271,1,Psychotic disorder
22039184,220391841,1,I,,20230215,20230227,20230227,EXP,,CA-APOTEX-2023AP003773,APOTEX,,54,YR,,M,Y,,,20230227,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,220391841,OT,,,,,,,,,220391841,1,HIV infection
22043195,220431951,1,I,,20230220,20230228,20230228,EXP,,CA-009507513-2302CAN007028,MERCK,,54,YR,,M,Y,,,20230228,,CN,CA,CA,EFAVIRENZ,Drug interaction;Psychiatric decompensation,220431951,OT,,,,,,,,,220431951,1,HIV infection
22043323,220433231,1,I,,20230217,20230228,20230228,EXP,,IN-AUROBINDO-AUR-APL-2023-002010,AUROBINDO,"Sivagourounadin K, Rajendran P, Selvarajan S, Ganesapandian M.. Agreement Among Different Scales for Causality Assessment in Drug-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.. Current Drug Safety. 2022;17(1):40-46",44,YR,,F,Y,,,20230228,,HP,IN,IN,EFAVIRENZ,SJS-TEN overlap;Stevens-Johnson syndrome;Toxic epidermal necrolysis,220433231,OT,,,,,,,,,220433231,1,Acquired immunodeficiency syndrome
22045722,220457221,1,I,,20230220,20230228,20230228,EXP,,CA-009507513-2302CAN007234,MERCK,,54,YR,,M,Y,,,20230228,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,220457221,OT,,,,,,,,,220457221,1,Product used for unknown indication
22047161,220471611,1,I,20120314,20230221,20230301,20230301,EXP,,IT-TAKEDA-2023TUS019137,TAKEDA,,45,YR,,M,Y,67,KG,20230301,,HP,IT,IT,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Tricuspid valve incompetence,220471611,OT,,,220471611,1,20050620,20141202,503,DAY,220471611,1,Prophylaxis
22052742,220527421,1,I,,20200324,20230302,20230302,EXP,,ZA-JNJFOC-20200338602,JOHNSON AND JOHNSON,,,,,,Y,,,20230302,,HP,ZA,ZA,EFAVIRENZ,Alanine aminotransferase increased;Anaemia;Electrocardiogram QT prolonged;Thrombocytopenia;White blood cell count decreased,220527421,OT,,,,,,,,,220527421,1,Pulmonary tuberculosis
22056108,220561082,2,F,20210913,20230221,20230302,20230303,EXP,,CN-GILEAD-2023-0617948,GILEAD,,30,YR,A,M,Y,80,KG,20230303,,HP,CN,CN,EFAVIRENZ,Angina pectoris,220561082,OT,,,220561082,1,20140730,20210224,2401,DAY,220561082,1,HIV infection
22056240,220562401,1,I,,20230228,20230302,20230302,EXP,,GB-GILEAD-2023-0618559,GILEAD,,,,,M,Y,,,20230302,,CN,GB,GB,EFAVIRENZ,Anxiety;Depressed mood;Drug interaction,220562401,OT,,,,,,,,,220562401,1,Product used for unknown indication
22058305,220583051,1,I,,20230222,20230303,20230303,EXP,,CO-CIPLA LTD.-2023CO01159,CIPLA,"Ardila-Suarez OM, Oriz-Benjumea L, Arteta AA, Guevara-Casallas LG. Drug-induced liver injury: Relation between the R ratio and histopathology. Journal of Gastroenterology of Mexico. 2023;88 (1):19 to 27",,,,,Y,,,20230303,,HP,CO,CO,EFAVIRENZ,Chronic hepatitis;Drug-induced liver injury;Hepatocellular injury,220583051,OT,,,,,,,,,220583051,1,HIV infection
22059942,220599421,1,I,,20230228,20230303,20230303,EXP,,GB-MYLANLABS-2023M1022754,MYLAN,,,,,M,Y,,,20230303,,CN,GB,GB,EFAVIRENZ,Anxiety;Depressed mood;Drug interaction,220599421,OT,,,,,,,,,220599421,1,Product used for unknown indication
22061346,220613461,1,I,,20230220,20230304,20230304,EXP,,IN-AUROBINDO-AUR-APL-2023-009426,AUROBINDO,"Parvez S, Goel P, Sarna MK, Rijhwani P. HIV-Associated Cutaneous Kaposi^s Sarcoma induced by IRIS following Antiretroviral Therapy. J-Indian-Acad-Clin-Med. 2022;23(3):154-156",30,YR,,M,Y,,,20230304,,HP,IN,IN,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,220613461,OT,,,,,,,,,220613461,1,HIV infection
22061663,220616631,1,I,,20221125,20230304,20230304,EXP,,CA-ABBVIE-4215253,ABBVIE,,63,YR,,F,Y,,,20230304,,MD,CA,CA,EFAVIRENZ,Alanine aminotransferase increased;Diarrhoea;Fatigue;Liver disorder;Low density lipoprotein increased;Mouth ulceration;Nausea;Nephrolithiasis;Osteoporosis;Renal disorder;Sleep terror;Type 2 diabetes mellitus,220616631,OT,,,,,,,,,220616631,1,Product used for unknown indication
22062007,220620071,1,I,,20230221,20230304,20230304,EXP,,ES-AUROBINDO-AUR-APL-2023-008823,AUROBINDO,"Hernanz-Lobo A, Ruiz Saez B, Carrasco Garcia I, Mino-Leon G, Juarez J, Pavia Ruz N et al.. New diagnosis of mother-to-child transmission of HIV in 8 Latin-American countries during 2018.. BMC Infectious Diseases. 2022;22(1)",4,YR,,,Y,,,20230304,,HP,ES,ES,EFAVIRENZ,Condition aggravated;Foetal exposure during pregnancy;HIV infection;Human immunodeficiency virus transmission;Virologic failure,220620071,OT,,,,,,,,,220620071,1,HIV infection
22063544,220635441,1,I,,20230222,20230306,20230306,EXP,,CO-CIPLA LTD.-2023CO01160,CIPLA,"Ardila-Suarez OM, Oriz-Benjumea L, Arteta AA, Guevara-Casallas LG.. Drug-induced liver injury: Relation between the R ratio and histopathology.. Journal of Gastroenterology of Mexico. 2023;88 (1):19 to 27",,,,,Y,,,20230306,,HP,CO,CO,EFAVIRENZ,Chronic hepatitis;Drug-induced liver injury;Hepatocellular injury,220635441,HO,,,,,,,,,220635441,1,HIV infection
22065473,220654731,1,I,,20230222,20230306,20230306,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2023-027227,BRISTOL MYERS SQUIBB,,54,YR,A,M,Y,,,20230306,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Hospitalisation;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,220654731,OT,,,,,,,,,220654731,1,HIV infection
22066492,220664921,1,I,,20230222,20230306,20230306,EXP,,CO-CIPLA LTD.-2023CO01161,CIPLA,"Ardila-Suarez OM, Oriz-Benjumea L, Arteta AA, Guevara-Casallas LG. Drug-induced liver injury: Relation between the R ratio and histopathology. Journal of Gastroenterology of Mexico. 2023;88 (1):19 to 27",,,,,Y,,,20230306,,HP,CO,CO,EFAVIRENZ,Drug-induced liver injury;Mixed liver injury,220664921,HO,,,,,,,,,220664921,1,HIV infection
22068272,220682721,1,I,,20230221,20230307,20230307,EXP,CA-MHPD-E2B_05970123,CA-Accord-303655,ACCORD,,54,YR,A,M,Y,,,20230307,,CN,CA,CA,EFAVIRENZ,Drug interaction;Psychiatric decompensation,220682721,OT,,,,,,,,,220682721,1,Depression
22073905,220739051,1,I,,20230302,20230308,20230308,EXP,,CN-GSK-CN2023GSK036255,GLAXOSMITHKLINE,,,,,,Y,,,20230308,,HP,CN,CN,EFAVIRENZ,HIV viraemia,220739051,OT,,,,,,,,,220739051,1,HIV infection CDC category B
22073906,220739061,1,I,,20230302,20230308,20230308,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK036255,VIIV,,,,,,Y,,,20230308,,HP,CN,CN,EFAVIRENZ,HIV viraemia,220739061,OT,,,,,,,,,220739061,1,HIV infection CDC category B
22074186,220741861,1,I,,20230302,20230308,20230308,EXP,,CN-GSK-CN2023GSK035121,GLAXOSMITHKLINE,,,,,,Y,,,20230308,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Virologic failure,220741861,OT,,,,,,,,,220741861,1,HIV infection
22074188,220741881,1,I,,20230302,20230308,20230308,EXP,,CN-GSK-CN2023GSK035120,GLAXOSMITHKLINE,,,,,,Y,,,20230308,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified;Virologic failure,220741881,OT,,,,,,,,,220741881,1,HIV infection
22074189,220741891,1,I,,20230302,20230308,20230308,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK035121,VIIV,,,,,,Y,,,20230308,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Virologic failure,220741891,OT,,,,,,,,,220741891,1,HIV infection
22074190,220741901,1,I,,20230302,20230308,20230308,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK035120,VIIV,,,,,,Y,,,20230308,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified;Virologic failure,220741901,OT,,,,,,,,,220741901,1,HIV infection
22074191,220741911,1,I,,20230302,20230308,20230308,EXP,,CN-GSK-CN2023GSK035119,GLAXOSMITHKLINE,,,,,,Y,,,20230308,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified,220741911,OT,,,,,,,,,220741911,1,HIV infection
22074192,220741921,1,I,,20230302,20230308,20230308,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK035119,VIIV,,,,,,Y,,,20230308,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified,220741921,OT,,,,,,,,,220741921,1,HIV infection
22074193,220741931,1,I,,20230302,20230308,20230308,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK035122,VIIV,,,,,,Y,,,20230308,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Virologic failure,220741931,OT,,,,,,,,,220741931,1,HIV infection
22074194,220741941,1,I,,20230302,20230308,20230308,EXP,,CN-GSK-CN2023GSK035122,GLAXOSMITHKLINE,,,,,,Y,,,20230308,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Virologic failure,220741941,OT,,,,,,,,,220741941,1,HIV infection
22074234,220742341,1,I,,20230302,20230308,20230308,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK035123,VIIV,,,,,,Y,,,20230308,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified;Virologic failure,220742341,OT,,,,,,,,,220742341,1,HIV infection
22074235,220742351,1,I,,20230302,20230308,20230308,EXP,,CN-GSK-CN2023GSK035124,GLAXOSMITHKLINE,,,,,,Y,,,20230308,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified;Virologic failure,220742351,OT,,,,,,,,,220742351,1,HIV infection CDC category B
22074236,220742361,1,I,,20230302,20230308,20230308,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK036253,VIIV,,,,,,Y,,,20230308,,HP,CN,CN,EFAVIRENZ,HIV viraemia,220742361,OT,,,,,,,,,220742361,1,HIV infection
22074237,220742371,1,I,,20230302,20230308,20230308,EXP,,CN-GSK-CN2023GSK035123,GLAXOSMITHKLINE,,,,,,Y,,,20230308,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified;Virologic failure,220742371,OT,,,,,,,,,220742371,1,HIV infection
22074238,220742381,1,I,,20230302,20230308,20230308,EXP,,CN-GSK-CN2023GSK036253,GLAXOSMITHKLINE,,,,,,Y,,,20230308,,HP,CN,CN,EFAVIRENZ,HIV viraemia,220742381,OT,,,,,,,,,220742381,1,HIV infection
22074239,220742391,1,I,,20230302,20230308,20230308,EXP,,CN-GSK-CN2023GSK036254,GLAXOSMITHKLINE,,,,,,Y,,,20230308,,HP,CN,CN,EFAVIRENZ,HIV viraemia,220742391,OT,,,,,,,,,220742391,1,HIV infection
22074240,220742401,1,I,,20230302,20230308,20230308,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK036254,VIIV,,,,,,Y,,,20230308,,HP,CN,CN,EFAVIRENZ,HIV viraemia,220742401,OT,,,,,,,,,220742401,1,HIV infection
22074241,220742411,1,I,,20230302,20230308,20230308,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK035124,VIIV,,,,,,Y,,,20230308,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified;Virologic failure,220742411,OT,,,,,,,,,220742411,1,HIV infection CDC category B
22074711,220747111,1,I,,20230302,20230308,20230308,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK035771,VIIV,,,,,,Y,,,20230308,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified,220747111,OT,,,,,,,,,220747111,1,HIV infection CDC category A
22074712,220747121,1,I,,20230302,20230308,20230308,EXP,,CN-GSK-CN2023GSK035772,GLAXOSMITHKLINE,,,,,,Y,,,20230308,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified;Virologic failure,220747121,OT,,,,,,,,,220747121,1,HIV infection
22074715,220747151,1,I,,20230302,20230308,20230308,EXP,,CN-GSK-CN2023GSK035771,GLAXOSMITHKLINE,,,,,,Y,,,20230308,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified,220747151,OT,,,,,,,,,220747151,1,HIV infection CDC category A
22074716,220747161,1,I,,20230302,20230308,20230308,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK035772,VIIV,,,,,,Y,,,20230308,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified;Virologic failure,220747161,OT,,,,,,,,,220747161,1,HIV infection
22075622,220756221,1,I,20090101,20230306,20230308,20230308,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-2023-033362,BRISTOL MYERS SQUIBB,,,,A,F,Y,,,20230308,,CN,PT,PT,EFAVIRENZ,Lipodystrophy acquired,220756221,OT,,,220756221,1,2001,,,,220756221,1,HIV infection
22077693,220776931,1,I,20210913,20230222,20230309,20230309,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023033979,VIIV,,,,,,Y,,,20230309,,HP,CN,CN,EFAVIRENZ,Angina pectoris,220776931,OT,,,220776931,1,20140730,20210224,2401,DAY,220776931,1,HIV infection
22077726,220777261,1,I,20210913,20230222,20230309,20230309,EXP,,CN-GSK-CN2023033979,GLAXOSMITHKLINE,,,,,,Y,,,20230309,,HP,CN,CN,EFAVIRENZ,Angina pectoris,220777261,OT,,,220777261,1,20140730,20210224,2401,DAY,220777261,1,HIV infection
22077813,220778131,1,I,,20230302,20230309,20230309,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK036087,VIIV,,,,,,Y,,,20230309,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified;Virologic failure,220778131,OT,,,,,,,,,220778131,1,HIV infection
22077815,220778151,1,I,,20230302,20230309,20230309,EXP,,CN-GSK-CN2023GSK036087,GLAXOSMITHKLINE,,,,,,Y,,,20230309,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified;Virologic failure,220778151,OT,,,,,,,,,220778151,1,HIV infection
22077871,220778711,1,I,,20230302,20230309,20230309,EXP,,CN-GSK-CN2023GSK036212,GLAXOSMITHKLINE,,,,,,Y,,,20230309,,HP,CN,CN,EFAVIRENZ,HIV viraemia,220778711,OT,,,,,,,,,220778711,1,HIV infection
22077872,220778721,1,I,,20230302,20230309,20230309,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK036210,VIIV,,,,,,Y,,,20230309,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified,220778721,OT,,,,,,,,,220778721,1,HIV infection
22077873,220778731,1,I,,20230302,20230309,20230309,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK036235,VIIV,,,,,,Y,,,20230309,,HP,CN,CN,EFAVIRENZ,HIV viraemia,220778731,OT,,,,,,,,,220778731,1,HIV infection
22077874,220778741,1,I,,20230302,20230309,20230309,EXP,,CN-GSK-CN2023GSK036236,GLAXOSMITHKLINE,,,,,,Y,,,20230309,,HP,CN,CN,EFAVIRENZ,HIV viraemia,220778741,OT,,,,,,,,,220778741,1,HIV infection
22077877,220778771,1,I,,20230302,20230309,20230309,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK036212,VIIV,,,,,,Y,,,20230309,,HP,CN,CN,EFAVIRENZ,HIV viraemia,220778771,OT,,,,,,,,,220778771,1,HIV infection
22077878,220778781,1,I,,20230302,20230309,20230309,EXP,,CN-GSK-CN2023GSK036235,GLAXOSMITHKLINE,,,,,,Y,,,20230309,,HP,CN,CN,EFAVIRENZ,HIV viraemia,220778781,OT,,,,,,,,,220778781,1,HIV infection
22077879,220778791,1,I,,20230302,20230309,20230309,EXP,,CN-GSK-CN2023GSK036210,GLAXOSMITHKLINE,,,,,,Y,,,20230309,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified,220778791,OT,,,,,,,,,220778791,1,HIV infection
22077880,220778801,1,I,,20230302,20230309,20230309,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK036236,VIIV,,,,,,Y,,,20230309,,HP,CN,CN,EFAVIRENZ,HIV viraemia,220778801,OT,,,,,,,,,220778801,1,HIV infection
22077881,220778811,1,I,,20230302,20230309,20230309,EXP,,CN-GSK-CN2023GSK036211,GLAXOSMITHKLINE,,,,,,Y,,,20230309,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified;Virologic failure,220778811,OT,,,,,,,,,220778811,1,HIV infection
22077882,220778821,1,I,,20230302,20230309,20230309,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK036211,VIIV,,,,,,Y,,,20230309,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified;Virologic failure,220778821,OT,,,,,,,,,220778821,1,HIV infection
22078372,220783721,1,I,,20230302,20230309,20230309,EXP,,CN-GSK-CN2023GSK036208,GLAXOSMITHKLINE,,,,,,Y,,,20230309,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified;Virologic failure,220783721,OT,,,,,,,,,220783721,1,HIV infection
22078373,220783731,1,I,,20230302,20230309,20230309,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK036208,VIIV,,,,,,Y,,,20230309,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified;Virologic failure,220783731,OT,,,,,,,,,220783731,1,HIV infection
22078612,220786121,1,I,,20230302,20230309,20230309,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK036209,VIIV,,,,,,Y,,,20230309,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified,220786121,OT,,,,,,,,,220786121,1,HIV infection
22078614,220786141,1,I,,20230302,20230309,20230309,EXP,,CN-GSK-CN2023GSK036209,GLAXOSMITHKLINE,,,,,,Y,,,20230309,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified,220786141,OT,,,,,,,,,220786141,1,HIV infection
22078944,220789441,1,I,,20230302,20230309,20230309,EXP,,CN-GSK-CN2023GSK036089,GLAXOSMITHKLINE,,,,,,Y,,,20230309,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified;Virologic failure,220789441,OT,,,,,,,,,220789441,1,HIV infection
22078945,220789451,1,I,,20230302,20230309,20230309,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK036089,VIIV,,,,,,Y,,,20230309,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified;Virologic failure,220789451,OT,,,,,,,,,220789451,1,HIV infection
22078946,220789461,1,I,,20230302,20230309,20230309,EXP,,CN-GSK-CN2023GSK036088,GLAXOSMITHKLINE,,,,,,Y,,,20230309,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified,220789461,OT,,,,,,,,,220789461,1,HIV infection CDC category B
22078947,220789471,1,I,,20230302,20230309,20230309,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK036088,VIIV,,,,,,Y,,,20230309,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified,220789471,OT,,,,,,,,,220789471,1,HIV infection CDC category B
22079007,220790071,1,I,,20230302,20230309,20230309,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2023GSK036090,VIIV,,,,,,Y,,,20230309,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified,220790071,OT,,,,,,,,,220790071,1,HIV infection
22079008,220790081,1,I,,20230302,20230309,20230309,EXP,,CN-GSK-CN2023GSK036090,GLAXOSMITHKLINE,,,,,,Y,,,20230309,,HP,CN,CN,EFAVIRENZ,HIV viraemia;Pathogen resistance;Viral mutation identified,220790081,OT,,,,,,,,,220790081,1,HIV infection
22086299,220862991,1,I,,20230308,20230310,20230310,EXP,,CA-BAUSCH-BL-2023-004053,BAUSCH AND LOMB,,54,YR,,M,Y,,,20230310,,CN,CA,CA,EFAVIRENZ,Drug interaction;Psychiatric decompensation,220862991,OT,,,,,,,,,220862991,1,Depression
22087150,220871501,1,I,,20230228,20230313,20230313,EXP,,GB-MACLEODS PHARMA EU LTD-MAC2023040140,MACLEODS,,,,,,Y,,,20230311,,CN,GB,GB,EFAVIRENZ,Anxiety;Depressed mood;Drug interaction,220871501,OT,,,,,,,,,220871501,1,Product used for unknown indication
22088611,220886111,1,I,20180829,20230308,20230313,20230313,EXP,,JP-VIIV HEALTHCARE LIMITED-JP2023JPN036936,VIIV,,,,,,Y,,,20230313,,MD,JP,JP,EFAVIRENZ,Insomnia;Syphilis,220886111,OT,,,220886111,1,20170130,20220611,1958,DAY,220886111,1,HIV infection
22090562,220905621,1,I,,20230307,20230313,20230313,EXP,,CA-009507513-2303CAN003083,MERCK,,,,,M,Y,,,20230313,,CN,CA,CA,EFAVIRENZ,Depression;Drug interaction,220905621,OT,,,,,,,,,220905621,1,Product used for unknown indication
22090586,220905861,1,I,,20230307,20230313,20230313,EXP,,CA-009507513-2303CAN003092,MERCK,,,,,M,Y,,,20230313,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,220905861,HO,,,,,,,,,220905861,1,Product used for unknown indication
22090734,220907341,1,I,,20230310,20230313,20230313,EXP,,US-GILEAD-2023-0620036,GILEAD,,64,YR,A,M,Y,,,20230313,,CN,US,US,SUSTIVA,Anxiety;Autonomic neuropathy;Brain neoplasm;Fatigue;Headache;Muscle atrophy;Terminal state;Unevaluable event,220907341,OT,,,,,,,,,220907341,1,HIV infection
22093874,220938741,1,I,,20230228,20230314,20230314,EXP,,GB-CIPLA (EU) LIMITED-2023GB01262,CIPLA,,,,,,Y,,,20230313,,CN,GB,GB,EFAVIRENZ,Anxiety;Depressed mood;Drug interaction,220938741,OT,,,,,,,,,220938741,1,Product used for unknown indication
22096710,220967101,1,I,,20230305,20230315,20230315,EXP,,IN-HETERO-HET2023IN00534,HETERO,"Joseph A, Cherian KE, Kapoor N, Paul TV. Tenofovir-induced hypophosphatemic osteomalacia: how do bone mineral density trabecular bone score and proximal hip geometry change with treatment?. Endocrinology, Diabetes + Metabolism Case Reports.. 2023;2023(1):1-5",46,YR,,F,Y,,,20230315,,HP,IN,IN,EFAVIRENZ,Hypophosphataemic osteomalacia;Renal tubular acidosis,220967101,OT,,,,,,,,,220967101,1,HIV infection
22097346,220973461,1,I,,20230302,20230315,20230315,EXP,,US-CIPLA LTD.-2023US01384,CIPLA,"Werbel WA, Brown DM, Kusemiju OT, Doby BL, Seaman SM, Redd AD et al. National landscape of human immunodeficiency virus-positive deceased organ donors in the United States. Clinical Infectious Diseases. 2022;74(11):2010 to 2019",,,,,Y,,,20230315,,HP,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Multiple-drug resistance,220973461,OT,,,,,,,,,220973461,1,HIV infection
22098405,220984051,1,I,,20230308,20230315,20230315,EXP,,CA-GSK-CA2023GSK038528,GLAXOSMITHKLINE,,,,,,Y,,,20230315,,CN,CA,CA,EFAVIRENZ,Drug interaction;Psychiatric decompensation,220984051,OT,,,,,,,,,220984051,1,Depression
22100706,221007061,1,I,,20230302,20230316,20230316,EXP,,IN-MACLEODS PHARMA EU LTD-MAC2023040244,MACLEODS,"Joseph A, Cherian KE, Kapoor N, Paul TV.. Tenofovir-induced hypophosphatemic osteomalacia: how do bone mineral density, trabecular bone score and proximal hip geometry change with treatment?. Endocrinology Diabetes Metabolism Case Reports. 2023;22:0259",,,,,Y,,,20230315,,HP,IN,IN,EFAVIRENZ,Hypokalaemia;Hypophosphataemic osteomalacia;Renal tubular acidosis,221007061,OT,,,221007061,1,,,12,YR,221007061,1,Antiretroviral therapy
22107824,221078241,1,I,20090101,20230306,20230317,20230317,EXP,,PT-AUROBINDO-AUR-APL-2023-011203,AUROBINDO,,,,A,F,Y,,,20230317,,MD,PT,PT,EFAVIRENZ,Lipodystrophy acquired,221078241,OT,,,221078241,1,2001,,,,221078241,1,HIV infection
22111608,221116081,1,I,20230222,20230308,20230318,20230318,EXP,,FR-MACLEODS PHARMACEUTICALS US LTD-MAC2023040299,MACLEODS,,,,,,Y,,,20230317,,CN,FR,FR,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abdominal pain;Depressed mood;Diarrhoea;Hyperhidrosis;Product dispensing error;Vertigo;Vomiting,221116081,OT,,,221116081,1,20230213,20230228,15,DAY,221116081,1,Prophylaxis against HIV infection
22113779,221137791,1,I,20230222,20230309,20230320,20230320,EXP,,FR-AUROBINDO-AUR-APL-2023-011860,AUROBINDO,,25,YR,,M,Y,65,KG,20230320,,CN,FR,FR,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abdominal pain;Depressed mood;Diarrhoea;Hyperhidrosis;Product dispensing error;Vertigo;Vomiting,221137791,OT,,,221137791,1,20230213,20230228,15,DAY,221137791,1,Prophylaxis against HIV infection
22114454,221144542,2,F,,20230317,20230320,20230323,EXP,FR-AFSSAPS-PC2023000309,FR-VIIV HEALTHCARE LIMITED-FR2023041159,VIIV,,,,,,Y,,,20230323,,MD,FR,FR,EFAVIRENZ,Hepatic cytolysis,221144542,OT,,,221144542,1,20221215,20230130,46,DAY,221144542,1,HIV infection
22117303,221173031,1,I,,20230310,20230320,20230320,EXP,,CA-TEVA-2023-CA-2868081,TEVA,,54,YR,A,M,Y,,,20230321,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,221173031,OT,,,,,,,,,221173031,1,HIV infection
22117317,221173171,1,I,,20230310,20230320,20230320,EXP,,CA-TEVA-2023-CA-2868083,TEVA,,,,,M,Y,,,20230321,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction,221173171,OT,,,,,,,,,221173171,1,Product used for unknown indication
22117321,221173211,1,I,,20230310,20230320,20230320,EXP,,CA-TEVA-2023-CA-2868085,TEVA,,54,YR,A,M,Y,,,20230321,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction;Incorrect route of product administration;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose;Product use in unapproved indication,221173211,OT,,,,,,,,,221173211,1,HIV infection
22118387,221183871,1,I,,20230306,20230321,20230321,EXP,,ZA-CIPLA LTD.-2023ZA01640,CIPLA,"Munsami L, Schutte CM, De Villiers M, Hiesgen J. Late-onset efavirenz toxicity: A descriptive study from Pretoria, South Africa. Southern African Journal of HIV Medicine. 2023;24(1):01 to 06",,,,,Y,,,20230321,,HP,ZA,ZA,EFAVIRENZ,Ataxia;Cerebellar atrophy;Loss of personal independence in daily activities;Mobility decreased;Toxicity to various agents;Wheelchair user,221183871,HO,,,,,,,,,221183871,1,HIV infection
22122696,221226961,1,I,20120521,20230208,20230321,20230321,EXP,GB-NOVPHSZ-PHHY2018GB086977,GB-ABBVIE-4300293,ABBVIE,,43,YR,,F,Y,43,KG,20230321,,MD,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Drug abuse;Maternal exposure during pregnancy;Off label use,221226961,DE,,,221226961,1,20100610,20180205,19,DAY,221226961,1,HIV infection
22127079,221270791,1,I,20221205,20230317,20230322,20230322,EXP,FR-AFSSAPS-PC2023000309,FR-GILEAD-2023-0620940,GILEAD,,57,YR,A,F,Y,114,KG,20230322,,MD,FR,FR,EFAVIRENZ,Hepatic cytolysis,221270791,OT,,,221270791,1,20220817,20230130,119,DAY,221270791,1,HIV infection
22127657,221276571,1,I,,20230313,20230323,20230323,EXP,,IN-AUROBINDO-AUR-APL-2023-012008,AUROBINDO,"Barman B, Jamil M, Dey B, Ish. Tuberculosis and human immunodeficiency virus coinfection complicated by immune reconstitution inflammatory syndrome.. Indian Journal of Sexually Transmitted Diseases and AIDS. 2022;43 (2):229-230",28,YR,,F,Y,,,20230323,,MD,IN,IN,EFAVIRENZ,Immune reconstitution inflammatory syndrome,221276571,OT,,,,,,,,,221276571,1,HIV infection
22134042,221340421,1,I,20221205,20230314,20230324,20230324,EXP,,FR-AUROBINDO-AUR-APL-2023-012688,AUROBINDO,,57,YR,,F,Y,114,KG,20230324,,MD,FR,FR,EFAVIRENZ,Hepatic cytolysis,221340421,OT,,,221340421,1,20220817,20221214,119,DAY,221340421,1,HIV infection
22135393,221353931,1,I,,20230316,20230324,20230324,EXP,,NVSC2023CA062943,NOVARTIS,,54,YR,,M,Y,,,20230324,,CN,CA,CA,EFAVIRENZ,Drug interaction;Psychiatric decompensation,221353931,OT,,,,,,,,,221353931,1,Depression
22138807,221388071,1,I,,20230314,20230327,20230327,EXP,,ES-MACLEODS PHARMACEUTICALS US LTD-MAC2023040379,MACLEODS,,,,,,Y,,,20230327,,HP,ES,ES,EFAVIRENZ,Disseminated tuberculosis;Drug interaction;Hepatotoxicity;Neurotoxicity,221388071,OT,,,,,,,,,221388071,1,Antiretroviral therapy
22139887,221398871,1,I,,20230321,20230327,20230327,EXP,,IN-STRIDES ARCOLAB LIMITED-2023SP004390,STRIDES,"Simon M, Meah A. Tenofovir as a cause of acquired fanconi^s syndrome. Ann-Afr-Med. 2023;22(1):128-130",53,YR,,F,Y,,,20230327,,HP,IN,IN,EFAVIRENZ,Fanconi syndrome,221398871,HO,,,,,,,,,221398871,1,HIV infection
22140031,221400311,1,I,,20230313,20230327,20230327,EXP,,ZW-CIPLA LTD.-2023ZW01606,CIPLA,"Mandikiyana Chirimuta LA, Pascoe MJ, Lowe S. Emergent dolutegravir resistance in integrase-naive, treatment experienced patients from Zimbabwe. Southern African Journal of HIV Medicine. 2022;23(1) a1435:1 to 3",,,,,Y,,,20230327,,HP,ZW,ZW,EFAVIRENZ,Drug interaction;Drug level below therapeutic;Multiple-drug resistance;Treatment noncompliance;Virologic failure,221400311,OT,,,221400311,1,202008,202006,,,221400311,1,HIV infection
22141984,221419841,1,I,20221205,20230320,20230327,20230327,EXP,FR-AFSSAPS-PC2023000309,FR-MYLANLABS-2023M1030294,MYLAN,,57,YR,,F,Y,114,KG,20230327,,MD,FR,FR,EFAVIRENZ,Hepatic cytolysis,221419841,HO,,,221419841,1,20220817,20230130,46,DAY,221419841,1,HIV infection
22144261,221442611,1,I,,20230315,20230328,20230328,EXP,,GH-CIPLA LTD.-2023GH01635,CIPLA,"Puplampu P, Ganu V, Asamoah I, Asare BO, Berko KP, Oladele O et al.. Cryptococcal meningitis among perinatally HIV-infected adolescents: Case series on presentation and management challenges. Clin Case Rep. 2023;11 (e6995):1 to 6",,,,,Y,,,20230328,,HP,GH,GH,EFAVIRENZ,Treatment noncompliance,221442611,OT,,,,,,,,,221442611,1,HIV infection
22153588,221535881,1,I,20230206,20230321,20230330,20230330,EXP,,PT-AUROBINDO-AUR-APL-2023-013663,AUROBINDO,,31,YR,,F,Y,,,20230330,,MD,PT,PT,EFAVIRENZ,Agitation;Insomnia;Irritability,221535881,DS,,,221535881,1,,20230316,,,221535881,1,HIV infection
22161643,221616431,1,I,,20230327,20230331,20230331,EXP,,GB-MYLANLABS-2023M1033438,MYLAN,,,,,F,Y,,,20230331,,CN,GB,GB,EFAVIRENZ,Hospitalisation,221616431,HO,,,,,,,,,221616431,1,Product used for unknown indication
6753908,675390818,18,F,20060602,20230103,20080911,20230111,EXP,,CA-MERCK-0809CAN00002,MERCK,"Harris M, Larsen G, Montaner JSG. Harris M, Larsen G, Montaner JSG. Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS. 2008;22 (14):1890-2. AIDS. 2008;22 (14):1890-2",44,YR,,M,Y,,,20230111,,MD,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,675390818,HO,,,675390818,1,20070626,20070626,2,DAY,675390818,1,HIV infection
6870591,68705916,6,F,,20230313,20081231,20230323,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-14455729,BRISTOL MYERS SQUIBB,"Harris M, Larsen G, Montaner JSG. Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS 2008;22(14):1890-2.",54,YR,A,M,Y,,,20230323,,MD,CA,CA,EFAVIRENZ;SUSTIVA,Anxiety;Depression;Depression suicidal;Drug interaction;Intentional product use issue;Loss of personal independence in daily activities;Off label use;Paranoia;Prescribed overdose;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation,68705916,DE,,,68705916,4,2004,,,,68705916,1,Bipolar disorder
7117171,711717116,16,F,,20230222,20090917,20230304,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-14780902,BRISTOL MYERS SQUIBB,"Pfeffer G, Cote HCF, Montaner JS, Li CC, Jitratkosol M, Mezei MM. Ophthalmoplegia and ptosis: mitochondrial toxicity in patients receiving HIV therapy. Neurology. 2009 Jul 07;73(1):71-2.doi:10.1212/WNL.0b013e3181aae814.",52,YR,A,M,Y,,,20230304,,MD,CA,CA,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia,711717116,OT,,,711717116,1,200802,,1189,DAY,711717116,1,HIV infection
7302622,730262244,44,F,,20230220,20100302,20230301,EXP,,CA-MERCK-0907CAN00093,MERCK,"Pfeffer G, Mezei MM, Montaner JS, Li CC, Jitratkosol M, Cote HC. Ophthalmoplegia and ptosis: mitochondrial toxicity in patients receiving HIV therapy. NEUROLOGY. 2009;73(1):71-2",52,YR,,M,Y,,,20230301,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Blood lactic acid increased;Diplopia;Dysphagia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,730262244,OT,,,730262244,1,200802,200802,91,DAY,730262244,1,HIV infection
7609977,760997729,29,F,20061128,20230309,20100928,20230317,EXP,,JP-JNJFOC-20100907113,JOHNSON AND JOHNSON,,49,YR,A,M,Y,,,20230317,,MD,JP,JP,EFAVIRENZ,Anaemia;Dyslipidaemia;Hepatocellular carcinoma;Hyperbilirubinaemia;Osteoporosis;Pyelonephritis,760997729,HO,,,760997729,1,20061111,20220927,6,YR,760997729,1,HIV infection
